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ABSTRACT 
 
DEVELOPMENT OF SPECIFIC AND POTENT α-HELICAL INHIBITORS AND 
PROBES OF CYSTEINE PROTEASES 
Nataline Meinhardt 
Doron Greenbaum, Ph.D. 
Cysteine proteases are of great scientific and pharmaceutical interest due to their diverse 
roles in cellular processes and diseases. However, it has been difficult to design inhibitors 
for use in determining their individual roles due to the conserved active site. 
Interestingly, each protease has an endogenous inhibitor that forms an α-helix at the 
prime side of the active site. We developed a new method for stabilizing α-helices using 
natural amino acids that allowed us to make small peptides into α-helical inhibitors. We 
were then able to use structure based design to turn these α-helices into specific 
inhibitors and probes for use in understanding the proteases’ roles in various diseases and 
cell processes. The use of α-helices has further implications as a new method of creating 
investigative tools for understanding proteases.  
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CHAPTER 1: Introduction  
	  
1.1 Introduction to Cysteine Proteases 
Cysteine proteases are enzymes that cleave peptide bonds using a catalytic dyad 
consisting of cysteine and histidine.1 The cysteine/histidine pair forms a thiolate-
imidazolium ion pair in which the thiolate ion nucleophilically attacks the carbonyl 
carbon in the peptide bond.2 This nucleophilic attack results in a thioester which is 
subsequently hydrolyzed There are multiple cysteine protease families. We are most 
interested in the papain superfamily, which is the largest of the cysteine protease families 
identified to date.3 The papain superfamily is named after the protease papain which was 
first isolated from the papaya. We are specifically interested in calpain-1 and cathepsins 
L, S, and K due to the presence of α-helices from the endogenous inhibitor or prodomain 
at each respective protease active site. 
 
Figure 1.1. Model of substrate association nomenclature.4,5 
Specificity of proteases usually relies on recognition of the amino acids around 
the scissile bond generally the three amino acids amino- or carboxyterminal to the scissile 
N
H
H
N
R
O
N
HO
R H
N
O
R
N
HO
R O H
N
R O
N
H
R
P3’ 
amino 
acid
P2’ 
amino 
acid
P1’ 
amino 
acid
P1 
amino 
acid
P2 
amino 
acid
P3 
amino 
acid
Unprimed sitesPrimed sites
Scissile Bond
N
-term
inusC
-te
rm
in
us
	   2	  
bond.6 Substrate amino acids are denoted by the letter P and enzyme substrate binding 
pockets are designated S; both are numbered according to their relative position to the 
scissile bond.4,6 This numbering has both prime (P’ or S’) and unprimed (P or S) 
denotations where the unprimed side is N-terminal to the scissile bond, while the prime 
side is C-terminal to the scissile bond (Figure 1.1).4 One of the main points of interest is 
the S1’ site which is a well defined pocket that can bind hydrophobic ring systems for π-
π stacking against a tryptophan.1 
1.2 Cysteine Protease Regulation and Cellular Location 
Proteases are regulated through a number of different mechanisms and located in 
a number of different cell types and various subcellular compartments within the cell. 
Calpain is regulated by both spatial, through relocation to the cell membrane, and 
temporal controls, through calcium flux and the endogenous, proteinaceous inhibitor 
calpastatin. Calpain-1 is a cytoplasmic protein generally found in all cells where it plays a 
role in proteolytic cleavage of the cytoskeleton.7 Other calpains are found in specific 
cells, such as calpain-3 which is primarily located in skeletal muscle.8 
Cathepsins are regulated by changes in pH and by the endogenous prodomain, 
which is cleaved upon activation but can still function as an inhibitor.9 Cathepsins are 
synthesized as an inactive proenzyme that is converted to active enzyme through 
autoproteolytic cleavage.10 Procathepsin is processed at low pH, hence cysteine 
cathepsins are normally found in acidic cellular compartments, i.e. in lysosome and 
endosomes.10,11 Cathepsin L is generally found in all cells while cathepsin K is found in 
osteocytes, and cathepsin S is almost exclusively found in antigen-presenting cells, B 
lymphocytes, and dendritic cells.3,11-13 
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Cysteine cathepsins are suggested to function in lysosomal protein degradation 
where they cleave a wide assortment of substrates.6,10 However, data increasingly 
supports the idea that cathepsins also function in extralysosomal activity such as at the 
plasma membrane or in the extracellular milieu.6 One such example of a cathepsin with 
extralysosomal activity is cathepsin K which is found in the bone resorption pit. The 
resorption pit has a low pH and this has led to the proposal that processing of the 
proenzyme may actually occur in this location.11 Due to their wide variety of locations 
cysteine proteases are involved in a number of diseases and cell functions 
1.3 Cysteine Protease Cellular Function and Role in Disease 
Cysteine proteases play critically important roles in cellular functions and disease. 
Cathepsin L functions to break down proteins in the lysosome and is involved in 
epidermal and cardiac homeostasis, prohormone processing, and autophagy.6 Cathepsin S 
is found primarily in the lysosome in antigen-presenting cells where it is involved the 
processing of the invariant chain, the chaperone molecule, of the MHC II complex.12-14 
Cathepsin K is excreted to the bone resorption pit where it plays a role in bone 
remodeling by breaking down collagen fibers in osteoclast mediated bone resorption.11 
Calpains are found in the cytoplasm and are known to breakdown cystoskeletal proteins, 
especially spectrin. As such they are suggested to play a role in cell migration and 
apoptosis.7 
Due to their roles within the cell, misregulation of cysteine proteases, either gain 
or loss of function, has been associated with numerous diseases.15 Cathepsin S has been 
suggested to be involved in rheumatoid arthritis, multiple sclerosis, asthma, and 
psoriasis.13 Cathepsin S also has elastase activity and subsequently has been implicated in 
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the pathogenesis of cardiovascular diseases like atherosclerosis and abdominal aortic 
aneurysm.13 Increased production of cathepsin S is also related to tumor progression and 
angiogenesis of cancer and consequently, an adverse outcome.16 Cathepsin L contributes 
to cancer cell proliferation, tumor growth, and resistance to therapy.6,17 Excessive 
cathepsin K activity associated with degradation of collagen fibers leads to osteoporosis 
and osteoarthritis.18 Calpains contribute to secondary degeneration after acute cellular 
stress such as myocardial ischemia, cerebral ischemia, or traumatic brain injury.19,20 
Hyperactivation of calpain is also correlated with amyloid diseases such as Huntington’s 
disease, Parkinson’s disease, and Alzheimer’s disease.21-23 
1.4 Prior Inhibitors of Cysteine Proteases 
Due to their role in disease there has been much interest in designing inhibitors of 
cysteine proteases. Most inhibitors are substrate mimetics that competitively block the 
active site of the protease by blocking substrate turnover.24 Often the inhibitors contain a 
peptide sequence with an additional reactive electrophilic moiety or ‘warhead’.17 This 
warhead covalently binds the catalytic cysteine either reversibly or irreversibly depending 
on the reactive group.17,24  
There are a number of different warheads used for cysteine protease inhibitors. 
Some early inhibitors used an epoxysuccinate, diazomethyl ketone, or fluoromethyl 
ketone to covalently and irreversibly react with the active site cysteine.5,16,25 The 
irreversibility and high potency of these inhibitors led to many off-target effects and 
possible metabolic consequences.16,24 Thus, efforts have shifted to develop reversible 
inhibitors. A few examples of the reversible warheads have been α-ketoamides16, 
nitriles26, and azepanones27,28.  
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There has been investigation into the variation of the warhead moiety, however 
these inhibitors have primarily focused on binding to pockets on the unprime side of the 
enzyme. Many of the issues associated with inhibitor development have been due to the 
inability to achieve selectivity due to the similarity of these unprimed side P1-P3 binding 
pockets of papain family cysteine protease active sites.5 Inhibitors design has even been 
extended as far as the P4 pocket in an effort to increase selectivity among the 
family.5,16,24,27,28 
In addition to synthesized inhibitors, cysteine proteases also have endogenous 
inhibitors. As mentioned earlier, the cathepsins are synthesized containing a proregion 
that acts as an endogenous inhibitor (Figure 1.2). In vitro studies have shown that the 
isolated propeptides retain their inhibitory activity and act as competitive tight binding 
inhibitors of the mature enzymes.29 The propeptides demonstrate some selectivity but not 
absolute specificity.9 Calpain, on the other hand, is not synthesized as a zymogen but 
relies on calcium binding for activation. However, calpain does have an endogenous 
proteinaceous inhibitor called calpastatin (Figure 1.2). In contrast to the cathepsin 
prodomains, calpastatin is absolutely specific for calpain. Interestingly, a trait all of these 
endogenous inhibitors share is a unique α-helix that sits at the active site blocking 
substrate binding.3,11,29,30 This α-helical structure and prime side binding present a unique 
avenue for cysteine protease inhibitor development. 
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Figure 1.2. Structures of zymogen cathepsins and calpastatin bound calpain. Zymogen forms of the 
cathepsins have a prodomain that functions as an endogenous inhibitor while calpain has an 
endogenous inhibitor called calpastatin. All of these endogenous, proteinaceous inhibitors have an α-
helix, denoted in green, that sits at the prime side of the active site, depicted in orange. (Cathepsin 
K:1BY8, Cathepsin L:1CS8, Cathepsin S:2C0Y, Calpain: 3BOW).3,11,29-31 
	  
1.5 α-Helix Stabilization Strategies 
The α-helices in the endogenous cysteine inhibitors present an interesting avenue 
for protease inhibitor development. Previously, α-helices have been synthesized as 
peptide mimetics of larger proteins, however when a small segment is excised from the 
parent protein it tends to lose its secondary structure. This loss of secondary structure 
results in reduced efficacy, permeability, and proteolytic stability.32 Thus, to increase the 
Cathepsin K Cathepsin L
Cathepsin S Calpain
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activity of these inhibitors, various techniques have been used to stabilize the α-helices 
prior to binding to the enzyme. 
A number of different methods have been utilized for α-helix stabilization; one of 
the most widely utilized is the ring closing olefin metathesis.  This method was first 
suggested by Blackwell et al., and it effectively introduces non-native carbon-carbon 
bond constraints.33 However, this initial work of Blackwell et al. did not show an 
enhancement of α-helical stability but rather the creation of a 310 helix.33 The Verdine 
laboratory improved upon this technique by using unnatural amino acids with R or S 
stereochemistry, i.e. Si,i+4S, Ri,i+4R, Ri,i+4S, Ri,i+7S, etc., and alkyl tethers of varying length 
(Figure 1.3).32,34 They found that α-helical stabilization increased as the ring size of the 
macrocyclic cross-link is increased.34 They subsequently named this technique 
hydrocarbon ‘stapling’.32,34  
A similar method for α-helix stabilization is the hydrogen bond surrogate 
developed by the Arora group.  Hydrogen bond surrogates use the ring closing metathesis 
to create alkyl linkages that mimic the length and location of the hydrogen bond.35-38 Due 
to the close mimicking of the hydrogen bond location this alkyl linker is on the ‘inside’ of 
the helix and does not block or remove solvent-exposed molecular recognition groups 
(Figure 1.3). The hydrocarbon stapling, by comparison, is on the ‘outside’ of the helix 
and uses the R-groups from two amino acids (Figure 1.3). A variation of the hydrogen 
bond surrogate contains a thioether instead of a double bond.39 The reaction conditions 
for this linkage are milder than ring closing metathesis, and the activity of the resulting 
α-helices are not affected.39 A downside of the hydrogen bond surrogate is that it uses the 
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amino terminus of the peptide in the linkage preventing the addition of a warhead at the 
N-terminus. 
Another side chain stapling method using mild linking conditions is the oxime 
linker developed by Haney et al. (Figure 1.3).40,41 The usefulness of this method is that 
not only can the peptide be linked in aqueous conditions but the linking strategy is 
reversible in water allowing for a dynamic mixture of linked and unlinked peptides.41 A 
negative aspect of this reversibility though is the unlinked moiety leaves itself open to 
proteolytic cleavage. 
 
Figure 1.3. Side chain and backbone linkages stabilize α-helices. Both the hydrocarbon stapling and 
oxime bridge create tethers using amino acid side chains while the hydrogen bond surrogate creates a 
bond mimicking the backbone hydrogen bond.31 
 
While the hydrocarbon stapling, hydrogen bond surrogate, and oxime linker 
methods have been used with good success, each method requires the incorporation of 
unnatural amino acids. A technique that doesn’t involve unnatural amino acids or harsh 
conditions involves the use of cysteine residues that nucleophilically attack halogenated 
Hydrocarbon Stapling Hydrogen Bond Surrogate Thioether Hydrogen Bond 
Surrogate
Oxime Bridge
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aromatics. Timmerman et al. first used this method to stabilize single, double, and triple 
loops rather than α-helices (Figure 1.4).42 Muppidi et al. adapted the technique to 
stabilize α-helices using a biphenyl motif to link two cysteines in an i, i+7 conformation, 
opposed to the i, i+4 conformation used in the other linking strategies (Figure 1.4).43 
 
Figure 1.4. Aromatic linkers stabilize loops and α-helices via thioether bonds. These linkers have 
been used to stabilize multiple loops as well as α-helices.31 
 
These different techniques of α-helical stabilization have been used to develop 
inhibitors, however these molecules have primarily been inhibitors of protein-protein 
interactions.44 These α-helical inhibitors include the stabilized BH3 domain of the Bcl-2 
family of proteins to inhibit Mcl-1 as a possible anti-cancer agent45, a stabilized α-helix 
from the NR coactivator peptide 2 to inhibit estrogen receptor α (ERα) for development 
of potential therapeutics for breast and endometrial cancer and osteoporosis46, stabilized 
Biphenyl Crosslinkage Triple Loop Stabilization
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α-helical p53 peptide to inhibit Mdm2 as a cancer therapy35,47, and a stabilized Jun-based 
inhibitor that binds to cFos as a step toward developing small molecule drugs for cancer 
and inflammatory diseases.48 These stabilized α-helices have been demonstrated to be 
specific and potent inhibitors of their respective protein-protein interactions.  
Some of the endogenous inhibitors and prodomains of cysteine proteases also 
have α-helices that bind to the respective protease. Based on the success of the α-helical 
inhibitors of protein-protein interactions and the presence of α-helical secondary 
structures in the prodomains of the cathepsins and the endogenous inhibitor of calpain-1, 
it can be postulated that a stabilized α-helix based may also be a good protease inhibitor.
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CHAPTER 2: Development of	  α-Helical Calpain Probes by Mimicking 
a Natural Protein-Protein Interaction	  
 
2.1 Introduction 
The primary goal of this work was to design and synthesize α-helical inhibitors as 
well as activity-based probes of human calpain, a calcium-regulated cysteine protease 
involved in a myriad of normal and pathological biological processes.49-60 Although there 
has been considerable interest in the design of α-helical peptides for the study of protein-
protein/receptor-ligand interactions and drug design, to our knowledge, there has been no 
work to date investigating α-helices as protease inhibitors. 
 
Figure 2.1. X-ray crystal structure of the calpain 2-calpastain complex (PDB ID: 3BOW). Key 
residues on the inhibitor, calpastatin, (purple) and calpain-2 (black) are labeled. 
 
The text of this chapter has been published. Reprinted with permission from Jo et al. Development of	  α-Helical Calpain 
Probes by Mimicking a Natural Protein-Protein Interaction. J Am Chem Soc, 2012. 134(42). Copyright 2014 American 
Chemical Society. 
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Inhibitor design for this class of enzyme has historically focused on the use of 
peptidomimetics that fit into the active site cleft in a substrate-like manner and utilize 
covalent, reversible or irreversible reactive groups to react with the active site cysteine.61-
68 The problems with this approach are twofold: 1) the papain superfamily has a highly 
conserved active site cleft, which complicates identification of peptidomimetic side 
chains that differentially bind to individual enzymes, and 2) small peptides do not bind 
well to calpains.   
To overcome this problem we took inspiration from the recent co-crystal structure 
of calpain with its endogenous protein inhibitor, calpastatin and from calpain inhibitors 
containing constrained scaffolds or macrocycles.30,69-72 Calpastatin is unstructured in 
solution; however, upon binding to active calpain it drapes across the entire protein and 
undergoes structural rearrangements to form three α-helices that contact three different 
domains of the enzyme. One of these α-helices binds adjacent to the prime side of the 
active site cleft (Figure 2.1), forming a number of energetically favorable interactions 
between apolar sidechains that become buried upon complex formation. We therefore 
hypothesized that this α-helical motif would provide increased specificity via its unique 
binding mode since the helix avoids the highly conserved region of the active site while 
still inhibiting substrate access to the active site cleft. 
This two-turn α-helix represents a ten-residue peptide. Previous work indicated 
that small peptides were poor inhibitors of calpains.7,73 We corroborated this idea by 
determining that the minimal calpastatin fragment peptide that formed the two-turn α-
helix (IPPKYRELLA) did not inhibit calpain (Ki >100 µM). We reasoned that the 
entropic cost of forming an α-helix from a random coil limited the ability of small 
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peptides to inhibit the enzyme; thus we decided to design a stabilized version of this 
peptide to minimize unfavorable conformational entropy.  
Several strategies have previously been developed for α-helix stabilization 
involving main- or side-chain modifications including: disulfide bond formation,74-76 
hydrogen bond surrogates,77,78 ring closing metathesis,33,79-81 cysteine alkylation using α-
haloacetamide derivatives82 or biaryl halides,43 lactam ring formation,83-89 hydrazone 
linkage,90 oxime linkage,91 metal chelation,92,93 and “click” chemistry.94,95 Of the 
different methods used to stabilize these structures, the inclusion of a semi-rigid cross-
linker96-104 has been particularly successful, and is explored herein.  
 
Figure 2.2  Conformational restriction via crosslinking (left).  Kinetic “selection of the fittest” 
reaction. Hypothetical rate constants are denoted by k1, k2, and k3 (right). 
 
2.2 Results and Discussion 
2.2.1 Design of template-constrained cyclic peptides stabilizing an α-helix conformation. 
Peptides are intrinsically flexible chains, which rapidly interconvert among a 
large ensemble of conformations, including canonical secondary structures (α-helices, 
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reversed turns, β-hairpins, etc.). Generally, only one of these conformations is required to 
bind a given receptor/enzyme, and very large changes in affinity (>104) can be realized 
by simply restricting the structure to a single conformational state.  
We were particularly interested in conformational restriction via cysteine 
alkylation105-108 for its chemical stability, selectivity, cost effectiveness, and ease of 
introduction via standard mutagenesis into recombinantly expressed peptides or proteins 
or by solid-phase peptide synthesis. Importantly, a number of structurally diverse thiol 
reactive crosslinkers are also commercially available. Thus, we envisioned that the 
bioactive conformation of a given peptide could be stabilized by identification of the 
optimal cysteine crosslinker from screening a library of crosslinkers on a peptide with 
two cysteines anchored in appropriate positions. We refer to α-helical peptides stabilized 
in this manner as template-constrained peptides.  
Figure 2.2 (left) shows the fundamental concept of template-constrained cyclic 
peptides, in this case accomplished via sidechain-to-sidechain cyclizations. To do this, a 
pair of cysteine residues is installed at appropriate positions in order to stabilize a local 
conformation. Here, we placed the cysteine residues at i, i+4 positions, because this 
spacing brings two thioether residues into proximity when in the α-helix. In a series of 
parallel reactions we react the peptide with an indexed array of different crosslinking 
agents. Bis-alkylators with sufficient reactivity to alkylate thiols will cleanly form cyclic 
peptides, if the macrocycle can be formed in a low-energy conformation that matches one 
of the low-energy conformations of the peptide. For example, a meta-xylyl group, which 
matches the inter-thiol distance of the cysteine sidechains when in an α-helical 
conformation, should stabilize this helical structure. By contrast, the much longer 
	  
	   15	  
distance of the 4,4’-biphenylmethyl group would not be consistent with the α-helical 
conformation, and would instead favor formation of a more extended conformation. 
Thus, depending on the template, it should be possible to stabilize any one of a number of 
conformations. 
We use a kinetic “selection of the fittest” method, to screen for only those linkers 
that help select stable, low-energy conformations over more strained conformations. The 
kinetic scheme for cyclization requires two steps (Figure 2.2, right): The first step 
involves the second-order alkylation of the dithiol-peptide, which depends on the 
concentration of both the alkylating agent and the peptide (rate 1 = 
k1[peptide(SH)2][alkylator]). The rate of this reaction depends on the chemical nature of 
the alkylator, but to the first approximation is largely independent of the peptide 
structure, which is largely in a random coil in the linear form. Once mono-alkylated, the 
second-order process of reacting with a second equivalent of the alkylating agent (rate 2 
= k2[peptide(SH)1][alkylator]) will compete with the desired first-order cyclization process 
(rate 3 = k3[peptide(SH)1]). (Solvolysis reactions of the mono-alkylated product also 
compete with cyclization.) The cyclization reaction depends on the ability of the peptide 
to reach a stable, strain-free conformation as it enters the transition state for cyclization, 
which we presume is geometrically similar to the product for large macrocyclic rings 
such as those formed here. Thus, the ratio of bis-alkylated to mono-alkylated compound 
provides a quantitative measure of the ease of cyclization that is dependent on the 
conformation of the cyclic form of the peptide. Bis-alkylation is dependent on the 
concentration of the peptide while cyclization is independent of this parameter, therefore 
it is possible to select for the most efficient crosslinkers by simply running the reaction at 
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a fixed peptide concentration with increasing concentrations of bis-alkylators and 
examining the product distribution by mass spectrometry.   
In summary, the current method of template-constrained thioether cyclization 
involves several steps: 1) Screening for cross-linking agents with appropriate reactivity 
and ability to form cyclic products under favorable conditions with nearly equimolar 
amounts of peptide and bis-alkylator. 2) Examining bis-alkylator “hits” with increased 
stringency, using higher molar concentrations of alkylators in large excess of the peptide. 
This step should provide template-constrained peptides with relatively strain-free 
conformations. 3) Testing the template-constrained peptides to determine which have 
been stabilized in the appropriate conformation. This can easily be accomplished by 
circular dichroism (CD) spectroscopy for an α-helix. 4) Finally, determining the impact 
of stabilizing the helix on the ability of the peptide to bind to a protein known to 
recognize the sequence in a helical conformation. 
To explore template-constrained cyclization to stabilize α-helices in aqueous 
solution, we used the model peptide 1 (sequence: Ac-YGGEAAREACARECAARE-
CONH2) which was similar to the FK-4 peptide previously described (Table S2.1 
Supporting Information).109 The model peptide exhibited a low to moderate level of 
helicity without any stabilization.  
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Scheme 2.1. Helix stabilization via screening of 24 crosslinkers. 
 
We screened twenty-four crosslinkers for cys-thioether macrocyclizations. The 
crosslinkers included alkyl bromides c1-c6, c12, and c13, alkyl iodides c7-c11, benzyl 
bromides c14-c20, allyl bromide c21, maleimides c22 and c23 and an electrophilic 
difluoro-benzene c24 (Scheme 2.1). The initial screening reaction was performed in a 96-
well plate format to identify crosslinkers that react with cysteine thiols under mild 
conditions (bicarbonate buffer, pH = 7.5 to 8.0) at room temperature. The crude reaction 
mixture was analyzed by MALDI-TOF mass spectrometry to identify any crosslinker that 
was a “hit”. Additional HPLC profiling can characterize product distribution. 
Product distribution was analyzed using MALDI-TOF and revealed that cysteine 
alkylation did not occur when simple alkyl halides c1-c12 were used; only intramolecular 
disulfide bond formation due to oxidation was observed to occur.110 Even when the 
leaving group was changed from bromide to the more reactive iodide c7-c11 alkylation 
reactions failed under these aqueous conditions. The crosslinking reaction with 1,4-
dibromo 2,3-butanedione c13 produced a complex mixture of products. Crosslinking 
reactions with the maleimide crosslinkers c22-c23 also resulted in a mixture of epimeric 
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products that were further complicated by hydrolysis of the imide (Figure S2.1 
Supporting Information). Reactions using 1,5-difluoro-2,4-dinitrobenzene c24 resulted in 
a similar complex mixture of products. For the biaryl derivatives c17, c18, predominantly 
unreacted peptide was detected (MALDI-TOF and HPLC) accompanied by traces of the 
desired, cyclized product (Figures S2.1 and S2.2 Supporting Information).  
The cleanest macrocyclization resulted from the reaction111,112 with 
benzylic/allylic halides c14-c16 and c19-c21, which provided the major peak of the 
cyclization product as seen by MALDI-TOF and HPLC trace analysis (Figures S2.1 and 
S2.2 Supporting Information). We then tested the crosslinker “hits” c14-c16 and c19-c21 
under the conditions designed to increase the rate of bis-alkylation over cyclization (by 
increasing the concentrations of alkylating agent and peptide in solution). HPLC analysis 
of the “selection of the fittest” showed that the 1,3-bis(bromomethyl) benzene (α,α’-
dibromo-m-xylene) crosslinker c15 and 2,6-bis(bromomethyl)pyridine crosslinker c20 
gave the cleanest formation of the desired macrocycle (Figure S2.3 Supporting 
Information). By contrast, crosslinking with allyl crosslinker c21 produced multiple 
peaks. It is interesting that the m-xylene crosslinker c15 was most successful crosslinker 
out of the three α,α’-dibromoxylenes c14-c16, considering that all the three alkylating 
agents have relatively different reactivity profiles (ortho>meta>para).106  
	  
	   19	  
 
Figure 2.3. CD spectra of the model peptide and the crosslinked peptides in phosphate buffer [50mM, 
pH=7.0, 25 oC]. 
 
We next evaluated the CD spectra of these selected template constrained cyclic 
peptides to determine the effect of the template on their coil-helix equilibria (Figure 2.3). 
The determination of secondary structure was complicated somewhat by the fact that the 
spectra are generally interpreted using the intensity of θ222, which requires knowledge of 
the concentration113, generally by measuring the absorbance of an N-terminal Tyr 
residue.  Some of our linkers contain aromatic groups that could absorb at 278 nm and 
complicate concentration determination.  Therefore, we use dry weight to estimate the 
concentration, which results up to a 25% error in concentration determination (assessed 
by comparing gravimetric versus spectrophotometric determination of peptides 
containing Tyr chromophores and lacking other groups). Because θ222 is not accurately 
measured, we therefore interpret the data largely based on the shape of the spectra, 
particularly the ratio of the peak shape and relative intensities of the two exciton-coupled 
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π-π’ bands at 190 nm and 208 nm relative to that of the n-π’ band near 222 nm.114 The 
three xylene-based crosslinkers c14-c16 all showed an increase of the helicity in the CD 
spectroscopy analysis. Notably, the m-xylene based crosslinker c15 showed the most 
increase in helicity followed by o-xylene c14 and finally p-xylene c16.   
Interestingly, the CD spectrum of the crosslinked peptides by crosslinkers c17 and 
c21 showed some structural differences from those seen using the xylene crosslinkers. As 
expected, the 4,4’-biphenyl (c17) crosslinked peptide showed little helicity, likely due to 
destabilization of the α-helix and stabilization of an extended conformation of the peptide 
because the end-to-end length of the biphenyl template is much longer than the typical α-
helix pitch. Likewise, peptide crosslinked with the butenyl derivative c21 showed a CD 
spectrum with a deep minimum near 200 nm, similar to that of the random coil (Figure 
2.3). It would be interesting to test whether this peptide, after the reduction of the double 
bond, could stabilize a 310 helix as shown in the Grubbs’s work33. This crosslinker could 
be an alternative to ring closing metathesis (RCM) stapling and subsequent double bond 
reduction strategy. 
Heterocyclic templates were also capable of stabilizing the α-helix. 2,3-
quinoxaline c19 and 2,6-pyridine c20 crosslinked peptides showed CD spectra similar to 
those of the o-xylene c14 and m-xylene c15 crosslinked peptides (Figure 2.3). 
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Figure 2.4. NMR of m-xylyl c15-constrained cyclic peptide (left). NOE sequential walk of backbone 
amide region of NOESY (250 ms) for the peptide. The cross peaks are labeled as NH(i)/NH(i + 1)  
3JNH-HA coupling as function of residue (right). The small 3JNH-HA(<6Hz) and strong sequential NH-
NH NOEs denote helix formation in the peptide. 
 
NMR spectroscopy experiments demonstrate that the cyclic template restraint 
strongly stabilized the helical conformation within the macrocyclic ring, and that the 
helix extended towards the C-terminus of the peptide (Figure 2.4). Typical stepwise 
NH(i)/NH(i + 1) NOE connections were observed from the first residue to the last 
residue, which are indicative of a helical conformation. Closer inspection showed that the 
cross-peak intensity became stronger after the residue 6, suggesting that the crosslinked 
region in the helix was more organized than frayed region of the N-terminus, which 
included two glycines. Furthermore, 3JNH-HA coupling was evaluated by the INFIT 
(inverse Fourier transformation of in-phase multiplets) procedure.115 The J coupling 
constant is a good indicator of secondary structure. It is generally averaged to ~7 Hz if 
the residue is in a random coil or in equilibrium between different structures. It is less 
than 6 Hz if it is in α-helical structure and is larger than 8 Hz if the secondary structure is 
a β-sheet. Our J coupling constant was mostly below 6 Hz suggesting an α-helical 
structure. In addition, the chemical shift index of α-H strongly demonstrated helix 
formation even in the fraying N-terminus. Secondary chemical shifts which were 
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calculated by subtracting the experimental values from the intrinsic values and clearly 
showed the effect of the crosslinker. The most dramatic changes were observed on 
Cys10, Ala11, Arg12 and Cys14, influenced in part by the anisotropy effect from the 
benzene ring in the crosslinker (Figure S2.4 Supporting Information). 
 
2.2.2 Application of i, i+4 m-xylene crosslinker-based stabilization for calpain inhibitor 
design. 
Turning back to calpain inhibitor design we chose to use the calpastatin fragment 
IPPKYRELLA (previously shown to be inactive against calpain) as the backbone since 
this sequence, in the context of full-length calpastatin, forms a two-turn helix in the prime 
side of the active site of calpain-1 as shown in figure 1. Three different sets of double 
cysteine mutants, 3a-c, along with their m-xylene crosslinked partners, 3a-c, were 
synthesized (Figure 2.5, Table S2.3 Supporting Information). Cysteine locations were 
chosen by both visual inspection and virtual alanine scanning mutagenesis (Table S2.2 
Supporting Information) so as not to disturb key interactions at the protein-helix 
interface, which includes Pro51 (inhibitor) ring stacking against Trp288 (calpain) and 
Tyr54 (inhibitor) H-bonding to His169 (calpain) as shown in Figure 1.  
 
Figure 2.5. Sequence of double cysteine mutants (3a, 3b, and 3c) and their crosslinked counterparts 
(3a, 3b, and 3c) (left). A helical wheel representation to indicate the crosslinked regions (right).116 
┌┐denotes the m-xylyl c15 crosslinking between the cysteines. 
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Next, the difference in structural changes as a result of cysteine crosslinking was 
examined via CD spectroscopy (Figure 2.6).113,117 The helical content of the 
uncrosslinked peptides was low in the absence of added trifluoroethanol (TFE), so the 
experiments were conducted in the presence of 40% TFE.118 CD analysis revealed a clear 
trend whereby all unlinked peptides showed little secondary structure, while the 
crosslinked peptides demonstrated varying degrees of α-helicity. Peptide 3c showed the 
greatest helicity after crosslinking, followed by 3b, while 3a showed negligible helicity 
after crosslinking. The lack of increased helicity for 3a may be due to the fact that it lacks 
the proline that is frequently found as an helix initiator of an α-helix.119 A possible salt 
bridge between the glutamic acid and lysine may also be enhancing helical content in 
3c.120-122 Thus, we believe that the primary sequence of the peptide as well as the 
crosslinker can influence the final helical content of the product peptide.  
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Figure 2.6. CD spectra of uncrosslinked peptides 3a-c (top) and crosslinked peptides 3a-c (bottom), 
[~125 µM peptide, 50 mM Tris (pH 7.5), 40% TFE]. Crosslinked peptide 3c demonstrates the 
greatest helical content. (See Figures S2.5 and S2.6 in Supporting Information for CD analysis 
without 40% TFE.)  
 
The inhibitors, both crosslinked and uncrosslinked, were tested for their ability to 
inhibit calpain-1 (Table 2.1, Figure S2.7 and S2.9 Supporting Information). No 
appreciable inhibition (Ki >100 µM) of calpain-1 was observed for the uncrosslinked 
peptides 3a-c. These results corroborate previous reports stating that the minimum length 
of a standard calpastatin derived peptide needed to achieve reasonable calpain inhibition 
is 27 amino acids long.123 However, the crosslinked peptide, 3c, which is only 10 amino 
acids long, showed good inhibition of calpain-1 in the low micromolar range (Table 2.1, 
Figure S2.9 Supporting Information). Furthermore, a trend relating higher helical content 
(Figure 2.6) positively correlated with better inhibition of calpain-1 (Table 2.1). This 
trend is likely directly related to helical content stabilized by the crosslinker c15, 
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although it is also possible that the crosslinker itself could contribute to enzyme 
recognition of the inhibitor. 
Peptide 3a 3b 3c 3a 3b 3c 
Calpain-1 
(µM) 
>100 >100 >100 >100 95.6 ± 25.5 10.2± 2.9 
Table 2.1 Ki against calpain-1. 124 The calpain assay was done as described in Materials and Methods. 
 
Kinetic studies were then performed to understand the mechanism of 3c inhibition 
of calpain-1; standard Michaelis-Menten and Lineweaver-Burke analysis showed that 3c 
behaved as a competitive inhibitor (Figure 2.7, Figure S2.10 and Table S2.4 Supporting 
Information). These results are consistent with the idea that 3c binds to the α-helix 
binding site in the primed side of the active site of calpain and physically blocks substrate 
binding, and subsequently proteolysis, as predicted from the initial co-crystal data (Figure 
2.1). 
 
Figure 2.7. Lineweaver-Burke analysis shows that calpain inhibitor 3c to be a competitive inhibitor. 
Lineweaver-Burke plot was constructed from standard Michaelis-Menten kinetics. 
 
There has been considerable difficulty in achieving good selectivity within the 
papain superfamily of enzymes as these enzymes contain highly conserved active 
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sites.30,125 To determine whether the helical inhibitor 3c was specific for calpain we tested 
it against a set of canonical papain family cysteine proteases including: papain, cathepsin 
B and cathepsin L (Table 2.2, Figure S2.11 Supporting Information). Significantly, no 
inhibition (Ki> 100 µM) was observed using the crosslinked peptide 3c against papain or 
cathepsin B. The inhibitor was about four fold more potent against calpain over cathepsin 
L (Ki=39.9 ± 1.09 µM). These results indicate that this α-helical motif may represent a 
uniquely selective binding element for inhibition of calpains and further validates our 
structure-based approach. Furthermore, structure activity relationship studies of these 
helical inhibitors may result in a more potent and specific inhibitors of calpain and also 
shed some light on to how the calpastatin helix interacts with human calpains.   
 
 
Table 2.2. The Ki of crosslinked inhibitor 3c against other papain family proteases.  
 
The crosslinking reaction was performed with the crosslinker c15 and the three 
peptides in aqueous buffer system. However, in instances where there are multiple 
cysteines, we believe that solid-phase cysteine crosslinking could be useful for selective 
crosslinking. To this end, we tested the on-resin crosslinking the peptide 3c. Fmoc-
Cys(Mmt)-OH was used instead of Fmoc-Cys(Trt)-OH and selective deprotection of 
specific cysteine side chains was achieved by 1% TFA/DCM treatment while the peptide 
was still resin bound.126,127 (See the Materials and Methods). The same kinetic results 
were achieved with on resin crosslinked inhibitor. 
Enzyme Calpain-1 Papain Cathepsin B Cathepsin L 
3c (µM) 10.2 ± 2.9 >100 >100 39.2 ± 1.1 
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Based on our initial success with a stabilized, α-helical-based inhibitor of calpain 
we next endeavored to develop an activity-based probe (ABP) specific for calpains. 
ABPs are complementary chemical tools to traditional genomic and proteomic 
techniques; ABPs are used for identification of enzymatic targets and to evaluate 
dynamics of enzyme activity regardless of levels of expression.128-133 This is important 
because in many cases translation and transcription do not correlate with enzyme 
activity134; this is especially true for calpains as their proteolytic activity is finely 
regulated post-translationally by intracellular calcium levels. Basic ABP design includes 
a mechanism based inhibitor, a specificity element, and a tag (Figure 2.8, top). In this 
case, the crosslinked peptide 3c was used for the specificity element and the succinyl 
epoxide functions as the warhead group that reacts with the cysteine thiol. This warhead 
has been established to react in a mechanism dependent manner only with active papain 
family proteases135. Three dipeptide linkers (NM-01, 02, and 03) of different lengths and 
rigidities were chosen via visual inspection in PyMOL31 based on the crystallographic 
structure of calpastatin-bound calpain 2 (PDB code 3BOW).30 Lastly, we chose to use 
either biotin or fluorescein isothiocyanate (FITC) as a tag. 
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Figure 2.8. Design of a calpain specific ABP (top). ABPs contain a mechanism based inhibitor, 
specificity element, and tag. Only the chemical structures ABPs containing a biotin tag are shown 
here. ┌┐denotes the m-xylyl c15 crosslinking between the cysteines. ABP binding to calpain-1 
(bottom). The linker length and rigidity between the crosslinked peptide and succinyl epoxide was 
evaluated via reaction with calpain-1 in vitro. A five-carbon backbone, flexible linker appears 
optimal. Loading control lanes beneath the panel show Western blot analysis using anti-calpain-1. 
 
We used three different amino acid sequences as linkers: alanine-alanine, β-
alanine-alanine, and alanine-β-homoproline, (NM-01, NM-02, and NM-03, respectively) 
(Table S2.5 Supporting Information). NM-01 is the shortest linker by one carbon but has 
similar flexibility as NM-02. NM-02 and NM-03 should cover a similar distance between 
the helix and succinyl epoxide, however the β-homoproline provides more rigidity than 
the β-alanine.  
To evaluate the best linker, we initially tested biotinylated versions of either NM-
01, -02, or -03 on purified, activated calpain-1 at two concentrations, 1 and 10 µM, and 
on unactivated calpain at 10 µM (Figure 2.8, bottom). Each ABP was added to purified 
calpain (pH 7.0), followed by the addition of calcium to activate the enzyme. The probe 
was allowed to react for 20 min. at room temperature. No calcium addition was used as a 
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control to demonstrate that labeling only occurred with active calpain, and DCG-04, a 
pan-papain family cysteine protease ABP135, was used as a positive control as it is known 
to label calpains. Samples were analyzed by SDS PAGE electrophoresis; proteins were 
transferred to PVDF membrane and analyzed by western blot for biotin using 
streptavidin-HRP. Our results show that two ABPs, NM-02 and NM-03, labeled calpain 
in an activity dependent manner, which indicated that an extra carbon in the amino acid 
backbone of the linker was necessary for the epoxide to react with the active site cysteine 
(Figure 2.8). The intensity of the bands in the blot suggested that the use of the linker β-
alanine-alanine resulted in the most potent probe (NM-02) (Figure 2.8, bottom). The ABP 
with the alanine-β-homoproline linker (NM-03) also bound to calpain but the rigidity in 
the linker induced by the pyrrolidine ring in homoproline may have contributed to less 
labeling. These results further support our hypothesis that the helix is binding at the 
active site as measurements of the probe visualized in PyMOL31 show that a β-alanine-
alanine linker would position the epoxide at the correct distance from the active site 
cysteine. 
The presence of the succinyl epoxide warhead could reduce the specificity of the 
inhibitor due to its reactivity against most papain family active site cysteines. However, 
based on the previous kinetic studies, we reasoned that if the crosslinked peptide bound 
to the enzyme followed by a covalent reaction between the warhead and the active site 
cysteine, the ABPs had a high probability of being specific for calpain despite the 
addition of this reactive warhead. To investigate the specificity of NM-02, we tested a 
FITC tagged NM-02 against calpain-1 and calpain-2, and a panel of papain family 
proteases including papain, cathepsin B, and cathepsin L (Figure 2.9). FITC-NM-02 was 
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added in increasing concentrations to either papain, cathepsin B, or cathepsin L and 
allowed to react for 20 min. at room temperature. Labeled enzymes were analyzed by 
SDS-PAGE and were visualized using a flatbed fluorescent scanner (Typhoon). We 
found that even at 10 µM, NM-02 did not bind to any of the other papain family cysteine 
proteases, which was in good agreement with the Ki (Table 2.2) determined in the 
binding studies of the crosslinked peptide 3c. This further suggests that NM-02 is specific 
for calpain at concentrations that would be appropriate for protease labeling experiments. 
 
Figure 2.9. FITC-NM-02 as a calpain specific ABP. We tested FITC- NM-02 (probe) in vitro against 
purified calpain-1, calpain-2, papain, cathepsin B, and cathepsin L. Only active calpain-1 and -2 are 
labeled and both are increasingly labeled with increased amounts of probe. Papain, Cathepsin B, and 
Cathepsin L are not labeled by NM-02. Loading control lanes beneath each panel show colloidal blue 
staining or silver staining of the respective gel. 
 
2.3 Conclusions 
In summary, we have demonstrated a simple screening of inexpensive, 
commercially available crosslinkers on an i, i+4 double cysteine mutant peptide to 
identify the best crosslinker to stabilize an α-helix. We identified five crosslinkers that 
increase α-helical character. Out of these five crosslinkers, dibromo-m-xylene, c15, 
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reacted in a simple, one-pot reaction, both in solution and on solid-phase, with the 
cysteine side chain and best increased the helicity of the peptide.  
We have also applied this helix stabilization method to mimic a protein-protein 
interaction between a protease and its endogenous protein inhibitor to create, to our 
knowledge, the first active site directed, α-helical inhibitor of a protease. Importantly, we 
demonstrate that this inhibitor is shows good potency and high specificity for calpains 
over other highly similar cysteine proteases.  
Lastly, we show that we can use the α-helical inhibitor as a scaffold to create an 
activity-based probe for examination of calpain activity. We determined that a β-amino 
acid is needed in the linker to bridge the gap between the helix and the active site 
cysteine. Furthermore it appeared that the ABP, NM-02, retained specificity for calpains 
over closely related cathepsin proteases. Given this specificity, we hope that these 
inhibitors and probes will allow for future studies of calpain function in multiple 
biological systems. We believe that the methodology used to stabilize this α-helical 
inhibitor will be another useful technique for α-helix stabilization for use in multiple 
biological applications. 
 
2.4 Materials and Methods 
2.4.1 Crosslinker Screen:  
To each well of a black round-bottomed 96-well plate (polypropylene) 90 µL of 
the stock solution, a peptide solution (0.114 mM) in NH4HCO3 buffer (12mL, 50 mM, 
pH=8.0), treated with TCEP (1M solution in the same NH4HCO3 buffer, 1.1 eq.) at room 
temperature (rt) for 1 h was added. Then 10 µL of the freshly prepared alkylating agent 
	  
	   32	  
solution (1.5 mM in anhydrous DMF, 1.5 eq.) was applied to the well at rt and stirred for 
2 h under protection from light. MALDI spectra were taken to monitor reaction progress 
and more alkylating agent was added if needed. The reaction was quenched by addition 
of 5% HCl which resulted in acidic conditions (pH=3-4). If necessary, 100 µL of ether 
was added to dissolve the excess reagent and organic byproducts into the organic layer. 
The ether layer could be removed by pipetting. MALDI spectra were taken from the 
sample in the remaining aqueous solution mixture. (Performed by H. Jo.) 
2.4.2 “Selection of the fitness” Screen:  
Screens were performed in 1.5 mL microcentrifuge tubes. 1 mL of the stock 
peptide solution (1mM) in NH4HCO3 buffer (50mM, pH=8.0) was pre-treated with TCEP 
as described above and incubated for 1 h.  Then, 100 µL of the concentrated alkylating 
agent solution (250mM or saturated solution in anhydrous DMF) was added and shaken 
for 2 h under protection from light. The reaction was quenched by the addition of 5% 
HCl which resulted in acidic conditions (pH=3-4) and purified by Reverse Phase HPLC. 
(Performed by H. Jo.) 
2.4.3 Crosslinking with the unpurified peptide:  
The lyophilized crude peptide solution (app. 3-5mg/mL) in NH4HCO3 buffer  
(100mM, pH=8.0) was treated with TCEP (1.5 eq.) and stirred for 1 h. The alkylating 
agent in DMF (app. 3eq) was added to the solution and shaken for the 2 h. The reaction 
was quenched by adjusting the pH of the mixture to slightly acidic conditions through the 
addition of 0.5 N HCl or TFA. The crude mixture was either purified by HPLC or 
lyophilized for the next step. 
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2.4.4 Preparation of crosslinked peptides 3c from model peptide 3c by solid-phase peptide 
crosslinking:  
The uncrosslinked peptide 3c was similarly prepared on the CLEARTM Rink 
Amide MBHA resin using the standard Fmoc peptide synthesis protocol (See Supporting 
Information). Fmoc-Cys(Mmt)-OH was used for cysteine for ease of deprotection. After 
the final coupling and cooling down to room temperature, the resin was washed with 
NMP(x3) and DMF(x3) followed by DCM(x3). The resin was then treated with 1% TFA 
solution in DCM for 10 min then washed with dichloromethane. This process was 
repeated until the solution lost its yellow color, which indicated the complete removal of 
Mmt protecting group. Then, the resin was washed with hexane and dried. After re-
swelling in DMF, a solution of α,α’-dibromo-m-xylene (2 eq.) in DMF and DIPEA (4 
eq) was added. Alternatively, the resin was re-swollen in NH4HCO3 buffer (pH=8.0, 100 
mM) for 1 h, a solution of α,α’-dibromo-m-xylene (5 eq.) in a minimal volume of DMF 
was added. The solution was stirred for 3 h at room temperature. The solvent was then 
removed and the resin was washed thoroughly with DMF. The Fmoc group on N-
terminus was removed by treatment with 20% piperidine in DMF and acetylated by Ac2O 
and DIPEA. The cleavage/deprotection was done using TFA/thioanisole/EDT/anisole 
(90/5/3/2). The crude mixture was purified by reverse phase HPLC. 
2.4.5 CD spectroscopy:  
Peptide solutions were prepared at ~50 µM in 50 mM phosphate buffer (pH 7.0) 
without TFE. The molar concentration of the peptide determined was by the weight (after 
lyophilization of the HPLC fractions) with consideration for molecular weight increase 
due to the presence of TFA salt for basic residues (Lys, Arg) as well as hydration 
(average 10%). Concentrations of the uncrosslinked peptides were determined by 
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absorbance of Tyr residue at 280 nm with an extinction coefficient of 1280 M-1 cm-1.136 
Circular dichroism studies were conducted at 25˚C on a JASCO J-810 spectropolarimeter 
equipped with a Peltier temperature control unit.  
2.4.6 NMR spectroscopy:  
The peptide sample was prepared with peptide concentrations of 2 mM in 0.6 mL 
of 9:1 v/v water/D2O mixture in 50 mM sodium phosphate, pH 5.5. All spectra were 
recorded at 10 oC on a Bruker Avance III 500 MHz spectrometer equipped with a 
cryogenic probe. All 2D homonuclear spectra were recorded with standard pulse 
sequences.137 Spectra were processed and analyzed using the programs nmrPipe138 and 
XEASY,139 respectively. (See Supporting Information.) (Performed by Y. Wu.) 
2.4.7 Protease Activity Assays:  
Peptides were evaluated for ability to bind and subsequently inhibit the cysteine 
proteases using standard proteolytic fluorescence activity assays. Inhibition was assayed 
using a standard donor-quencher strategy using a previously published peptide 
substrates.62,140,141  
Enzyme concentration for Calpain-1 was 25 nM. Enzyme concentration for 
papain was 25 nM. Enzyme concentrations for cathepsin B and cathepsin L was 3 nM.  
Calpain and papain buffer contained 10 mM dithiothreitol (DTT), 100 mM KCl, 2 mM 
EGTA, 50 mM Tris-HCl (pH 7.5), and 0.015% Brij-35. Substrate concentration for 
calpain and papain was 0.25 µM H-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-
OH (Km calculation in Supporting Information, Figures S2.8 and S2.10).62,140,141 
Cathepsin buffer contained 10 mM DTT, 500 mM sodium acetate (pH 5.5), and 4 mM 
EGTA.62,140,141 Substrate concentration for the cathepsins was 0.25 µM Z-FR-Amc. 
Calpain was activated by the injection of CaCl2 to a final concentration of 5 mM. Papain 
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and cathepsin assays were activated by the addition of the substrate via a multichannel 
pipette. Varying concentrations of inhibitor, 1-100 µM, were used for each assay. All 
assays were done at a total well volume of 100 µL in 96-well plate, and each well 
contained a separate inhibitor concentration. Fluorescence was read in a Berthold Tri-Star 
fluorimeter. The excitation wavelength was 380 nm and the emission wavelength was 
500 nm for H-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH. The excitation 
wavelength 351 nm and emission wavelength was 430 nm for Z-FR-Amc. 
2.4.8 Kinetic analysis of Calpain-1 by 3c:  
To identify inhibition type we used standard Michaelis-Menten treatment. Initial 
velocities (obtained from the linear segment of the progress curves) were plotted against 
substrate concentration.142 Due to the linearity of the first segment of the progress curve 
we believe that autoproteolysis during the first 500 seconds was not substantial enough to 
prevent the use of simple Michaelis-Menten kinetics, i.e. loss of enzyme did not change 
the velocity enough to cause it to deviate from linearity and incorporation of this 
additional complex would severely complicate the kinetics. Velocities were determined 
in RFU/sec then converted to µM/sec using the conversion factor 1386 RFU/µM. The 
conversion factor was obtained by the total hydrolysis of the substrate H-Glu(Edans)-Pro-
Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH in a known concentration by papain. To avoid 
weighting errors we used the values of Kmapp and Vmaxapp determined directly from the 
non-linear least-squares best fits of the untransformed data and put these values into the 
reciprocal equation: 
€ 
1
v
= ( Km
Vmax
×
1
[S]
) + 1
Vmax
.142 
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We then plotted the resulting reciprocal velocities against the respective 
reciprocal substrate concentrations. 
2.4.9 Determination of IC50 against Enzymes:  
IC50 curves were generated identifying the initial rate of the enzyme at each 
inhibitor concentration from the respective progress curves. The conversion factor (1386 
RFU/µM) was obtained by the total hydrolysis of the substrate H-E(Edans)-PLFAER-
K(Dabcyl)-OH in a known concentration by papain. Initial velocities were converted 
from RFU/sec to µM/sec. Fractional activity was calculated by dividing the initial 
velocity at each inhibitor concentration by the initial velocity of the uninhibited enzyme. 
Data obtained up to 500 seconds was used for the initial rate calculation. The initial rate 
was then plotted against the log of the inhibitor concentration, and IC50 was calculated by 
GraphPad Prism.  
2.4.10 Activity Based Probe Linker Experiments:  
Experimental conditions included 10 mM dithiothreitol (DTT), 1.5 µg calpain, 
100 mM KCl, 2 mM EGTA, 50 mM Tris-HCl (pH 7.5), 0.015% Brij-35, and either 1 µM 
or 10 µM of biotinylated probe (DCG-04, NM-01, NM-02, NM-03). Calpain was 
activated by the addition of calcium (3.33 µM of 50 mM CaCl2) to a final concentration 
of 8.3 mM in tubes containing either 1 µM or 10 µM ABP. For the negative control, 
water, instead of CaCl2, was added to the calpain solution containing 10 µM probe. 
Probes were allowed to bind to the calpain for 20 minutes at room temperature. The 
reaction was stopped by the addition of 10 µL NuPage® LDS Running Buffer (Life 
Technologies, Grand Island, NY). 10 µL of each labeled enzyme was loaded on a 10% 
Bis-Tris NuPAGE® gel (Life Technologies, Grand Island, NY) and separated via gel 
electrophoresis for 1.5 h, 140 V. The bands were then transferred to a PVDF membrane 
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at 30 V for 70 min. The membrane was blocked and blotted using the Vectastain® Elite® 
ABC kit (Vector Laboratories, Burlingame, CA). Kodak film was exposed to the 
membrane and developed. 
2.4.11 ABP Labeling Experiments:  
Buffer conditions for calpain and papain experiments were 10 µM dithioreitol 
(DTT), 100 mM KCl, 2 mM EGTA, 50 mM Tris-HCl (pH 7.5), and 0.015% Brij-35. 1.5 
µg calpain-1 or 6 µg calpain-2 (calpain-2 was not as active) was used. (For labeling 
experiments greater concentrations of enzyme were used for ease of visualization of the 
enzyme on stained gels.) Buffer conditions for cathepsin experiments were 10 µM DTT, 
500 mM sodium acetate (pH 5.5), and 4 mM EGTA. 1.5 µg of each cathepsin was 
labeled.62,140,141 Probes were allowed to bind for 20 min. at room temperature. Labeled 
enzymes were separated via gel electrophoresis on 10% (calpain, papain) or 12% 
(cathepsins) Bis-Tris NuPAGE® gels for 1 hr, 140 V. A Typhoon Fluorescent Imager was 
used for FITC visualization of the probe bound enzyme. Following fluorescent scanning 
the gels were colloidal blue stained (calpain-1 and calpain-2) or silver stained (papain, 
cathepsin B, and cathepsin L) to demonstrate that the same amount of enzyme had been 
used in all lanes. (See Supporting Information).  
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CHAPTER 3: Development of Potent and Specific Inhibitors and 
Quench Activity Based Probes for Calpain-1 
 
3.1 Introduction 
Calpain-1 is a cysteine protease involved in a number of cell processes such as 
cell migration and apoptosis and diseases states such as amyloid diseases and secondary 
cell death after acute cellular stress.19-23 There has been substantial interest in designing 
inhibitors and probes of calpain-1 in order to investigate the role it plays in these 
diseases. However, a large hurdle to overcome in the development of these investigative 
tools is the conserved active site of the papain family cysteine proteases. Endogenous 
inhibitors and substrates can be good starting points for the development of specific 
inhibitors. Calpain has an absolutely specific endogenous inhibitor called calpastatin and 
a commercially available fairly specific substrate.30,69,140,143 Either one or both of these 
molecules can be starting points for the development of new calpain inhibitors and probes 
to investigate the role calpain plays in both cellular function and disease. 
We have previously developed a small ten amino acid two-turn α-helical potent 
and specific inhibitor for calpain based on the endogenous inhibitor calpastatin. We 
further were able to add an epoxysuccinic warhead to the inhibitor to create a specific 
activity based probe. However, there are still improvements to be made to create a more 
potent and specific inhibitor and probe.  
3.2 Results and Discussion 
3.2.1 Alanine Scanning Mutagenesis to Identify Residues Important for Enzyme Binding 
To improve upon the ten amino acid inhibitor, alanine scanning was performed to 
identify important residues for binding to the enzyme and to identify where mutations in 
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the ten amino acid peptide could be introduced (Table S3.1 Supporting Information). 
Alanine scanning mutagenesis involves mutating each amino acid in the peptide to 
alanine to identify how each amino acid affects the potency and specificity of the 
inhibitor.  
 Inhibitor Calpain-1 (µM) 
3c IPPKYCELLC 10.2 ± 2.9 
3d APPKYCELLC 65.6 ± 20.5 
3e IAPKYCELLC 13.7 ± 4.4 
3f IPAKYCELLC 27.4 ± 5.6 
3g IPPAYCELLC 17.7 ± 5.6 
3h IPPKACELLC >100 
3i IPPKYCALLC 28.9 ± 9.1 
3j IPPKYCEALC 30.9 ± 9.2 
3k IPPKYCELAC 25.2 ± 7.9 
Table 3.1 Alanine Scanning Mutagenesis. Ki for each alanine mutant against calpain-1. 
 
Alanine scanning mutagenesis identified isoleucine and tyrosine as the most 
important residues for inhibitor binding to calpain due to the substantial loss of potency 
in each of these mutants (Figure S3.1, Table S3.2 Supporting Information). This result 
correlates the findings in a β−Alanine scanning study done by Betts et al., which 
identified this isoleucine to be important for inhibition in the 27 amino acid calpastatin 
derivative.123,144 The aliphatic chain of the isoleucine projects into the prime side cleft to 
form a hydrophobic interaction with Ala101 and Leu102.30 Further mutational studies 
reinforce the hypothesis that the branched aliphatic side chain is necessary for retaining 
potency as a IleLeu mutation has no effect upon calpain inhibition or specificity, while 
a mutation to a similar sized branched polar side chain, IleGln, did reduce the potency 
(Figure S3.2, Tables S3.3 and S3.4 Supporting Information).  
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Tyrosine appears to be fitting into a cleft lined with E164 and H169 suggesting 
that it might be forming electrostatic interactions with either glutamate or histidine or π-π 
stacking interactions with the H169. A mutation of tyrosine to Ala(4,4’-biphenyl) 
resulted in no change in Ki while a benzyl tyrosine mutation caused an increase in Ki 
suggesting that ring stacking may play a larger role in potency than electrostatics (Figure 
S3.2, Table S3.3 and S3.4 Supporting Information). It must be acknowledged, though, 
that these results are not conclusive as both mutant side chains are substantially larger 
than the tyrosine side chain, and subsequently steric hindrance could also play a role. 
These groups were introduced because it was thought that they might fit into the large 
cleft where the tyrosine resides and create more interactions between the inhibitor and 
enzyme.  
Alanine mutations of the N-terminal proline, P1, and lysine, 3e and 3g 
respectively, have no effect on inhibitor potency suggesting that these are key locations 
for potential mutations. The P1 residue stacks against Trp288.30 Mutating this proline to 
an aromatic residue could increase the π-π interactions with tryptophan thereby 
increasing the binding affinity. Interestingly, P1 is also important for specificity. The 
alanine mutant 3e resulted in a substantial decrease in specificity, especially against 
cathepsin L (Table S3.2 Supporting Information). The proline was mutated to 
pentafluorophenylalanine, pfF, 4a, which decreased the Ki by half while retaining the 
same specificity for calpain over cathepsin L and improving specificity against cathepsin 
S (Table 3.2, Figure S3.3 and Table S3.5 Supporting Information).  
The lysine residue of inhibitor 3c sits between calpain residues Glu164 and 
Gln290. Increasing electrostatic interactions in this region may be accomplished by 
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mutating the lysine to a more positive residue such as arginine. The guanidinium group 
on the arginine may also enable multiple hydrogen bonds to these surrounding residues. 
This LysArg mutation, 4b, results in a decrease in Ki to 5 µM (Table 3.2). Similarly to 
the pentafluorophenylalanine mutation the LysArg mutation also resulted in an 
increase in specificity against cathepsin L and S (Table 3.2, Figure S3.3 and Table S3.5 
Supporting Information).  
Interestingly, when these two mutations are combined, 4c, the potency of the 
inhibitor is lost (Table 3.2, Figure S3.3 and Table S3.5 Supporting Information). This loss 
of potency could suggest that one or both of the mutations change the orientation of the 
α-helical inhibitor in the prime side of the active site creating clashes between the 
inhibitor and enzyme. 
All other alanine mutations resulted in 3-fold loss of potency of the inhibitor. This 
loss of potency could be due to a loss of α-helicity, reduction of binding interactions, or a 
change in binding orientation because of the change in the amino acid side chain.  
 Inhibitor Calpain-1 (µM) Cathepsin L (µM) Cathepsin S (µM) 
4a IpfFPKYCELLC 5.1 ± 1.9 22.2 ± 1.1 >100 
4b IPPRYCELLC 5.3 ± 2.0 37.9 ± 1.1 35.9 ± 1.1 
4c IpfFPRYCELLC 37.1 ± 11.6 NT NT 
pfF=pentafluorophenylalanine; NT=Not Tested 
Table 3.2 Mutant calpain-1 inhibitors. Ki for each mutant inhibitor for calpain-1. Each single mutant had 
improved potency against calpain-1, however the double mutant had reduced potency against calpain-1. 
3.2.2 Increasing Potency Through Increasing Peptide Length 
Peptide 3c was modeled after a two-turn α-helix that binds at the calpain active 
site in the endogenous calpain inhibitor calpastatin. Previous studies demonstrated that 
the shortest, effective, non-stabilized inhibitor was 27 amino acids. The Anagli group 
demonstrated that truncating the inhibitor from the N-terminus resulted in a sequential 
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decrease in inhibition.123 The shortest, non-stabilized fragment tested was 19 amino acids 
long and had an IC50 of 1.8 ± 0.016 µM. From this information, it was hypothesized that 
lengthening the inhibitors would also result in an increase in inhibition, while the 
stabilization of the α-helix would still allow the inhibitor to be substantially shorter than 
the previous calpastatin fragments.  
To evaluate this hypothesis, inhibitors of varying lengths were synthesized. 
During the development of the calpain probe, a linker of alanine and β-alanine was added 
between the α-helical inhibitor and the epoxysuccinic acid warhead. This linker 
lengthened the peptide to a 12 amino acid peptide, 5a, however these additional amino 
acids did not increase the potency of the inhibitor (Table 3.3, Figure S3.4 and Table S3.6 
Supporting Information). This lack of increased potency may be due to the absence of 
side chains that interact with the enzyme. Therefore, the calpastatin amino acid sequence 
was used to extend the inhibitor. The first lengthened inhibitor, 5b, was 13 amino acids 
and had a Ki of 5.3 ± 1.9 µM (Table 3.3, Figure S3.4 and Table S3.6 Supporting 
Information). Further analysis of the unstabilized 13-mer supports the idea that additional 
enzyme contacts help overcome the free energy needed for binding, however, 13 amino 
acids is not long enough to get good inhibitory activity (Tables S3.7 and Table S3.6 
Supporting Information). Extending the inhibitor to 17 amino acids, 5c, creates an 
inhibitor slightly shorter than the shortest non-stabilized inhibitor tested by Betts et. al.123 
This inhibitor extends past the active site into the unprimed side of the enzyme where 
leucine interacts with the P2 pocket.30,69 It includes the loop over the active site and 
resulted in an inhibitor with a Ki of 3.6 ± 1.7 µM (Table 3.3, Figure S3.4 and Table S3.6 
Supporting Information).  
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Finally, 5d was synthesized where the glycine was mutated to phenylalanine 
resulting in a removal of the loop over the active site and subsequent increase in the 
number of N-terminal interactions. This inhibitor results in a Ki of 1.2 ± 1.3 µM which is 
very similar to the IC50 from the unstabilized 19-mer (Table 3.3, Figure S3.4 and Table 
S3.6).123 These results imply that stabilizing the α-helix does improve inhibitor potency.  
 Inhibitor Calpain (µM) Cathepsin L (µM) Cathepsin S (µM) 
5a βAAIPPKYCELLC 10.7 ± 3.5 42.0 ± 1.3 38.4 ± 1.1 
5b EVTIPPKYCELLC 5.3 ± 1.9 69.6 ± 1.5 31.3 ± 1.2 
5c LGKREVTIPPKYCELLC 3.6 ± 1.7 >100 31.5 ± 1.1 
5d LFKREVTIPPKYCELLC 1.3 ± 1.3 10.7 ± 1.1 41.5 ± 4.5 
Table 3.3 Calpain-1 inhibitors of increasing peptide length. The Ki of each calpain-1 inhibitor of 
increasing length. The potency of the inhibitors tends to increase with longer peptides, however the 
presence of side chains seems to influence the potency.  
 
Lengthening the stabilized peptide into the unprimed region does have an effect 
upon potency, however simple length addition does not implicitly increase potency, 
sequence also seems to have an effect upon Ki. 
3.2.3 Developing Quench Probes 
Previously, an activity based probe or ABP was created by adding a fluorophore 
tag, amino acid linker, and electrophilic warhead to the stabilized α-helical inhibitor. This 
ABP binds only active enzyme and was fairly specific for calpain. However, the 
attachment of a fluorophore tag means that there will always be substantial background 
fluorescence, which could interfere with visual identification of proteases.145-147 One way 
to overcome the background fluorescence is through the use of a quench probe. A quench 
probe contains a donor fluorophore and a quencher, which absorbs fluorescence in the 
same wavelength range that the donor emits. Upon binding to the enzyme this quencher 
is removed and the enzyme can then be visualized by the fluorophore.145-147 
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Our proposed method for removing the quencher from the probe post enzyme 
binding was to attach a cleavable sequence to the N-terminus of the α-helical inhibitor. 
The results of the lengthening studies suggest that the inhibitor can be extended at the N-
terminus with little detriment to potency, and in some cases may actually increase 
potency. Previously, no cleavage product could be isolated from peptide 5d after 
cleavage assays suggesting that simply laying across the enzyme active site is not 
sufficient for proteolysis by calpain. The addition of the substrate sequence rather than 
the calpastatin inhibitor sequence ensured that the quencher is actually cleaved from the 
inhibitor.  
The initial substrate sequence chosen was Pro-Leu-Phe-Ala-Ala-Arg because this 
sequence has been determined to be a preferred calpain-1 substrate sequence.143 The 
scissile bond is found between the phenylalanine and alanine. This substrate sequence 
was added to the N-terminus of the α-helical inhibitor for a final amino acid sequence of 
Pro-Leu-Phe-Ala-Ala-Arg-Ile-Pro-Pro-Lys-Tyr-Cys-Glu-Leu-Leu-Cys-Lys (6a). The 
lysine was added at the C-terminus for future fluorophore addition similar to the ABP 
developed previously. Initial analysis of this substrate/inhibitor found that it was also cut 
between the phenylalanine and alanine demonstrating that this was a potentially good 
sequence for the quench probe.  
Studies found that the addition of a charged residue at the C-terminus negatively 
affected enzyme binding, thus the location of the fluorophore had to be moved closer to 
the N-terminus (Figure S3.5, Tables S3.58 and S3.9 Supporting Information). We used 
Edans and Dabcyl as the donor and quencher respectively. This is the same 
donor/quencher pair found in the commercially available substrate (sequence: NH2-
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Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH; Dabcyl is attached to a lysine 
and Edans is attached to a glutamate.) In both peptides the quencher is at the N-terminus. 
We synthesized two peptides with donor fluorophores at different positions. In one 
quench probe the donor was situated between the substrate sequence and inhibitor 
sequence, Lys(Dabcyl)-Pro-Leu-Phe-Ala-Ala-Arg-Glu(Edans), 6c. In the other quench 
probe, the donor was within the substrate sequence, Lys(Dabcyl)-Pro-Leu-Phe-Ala-
Glu(Edans)-Arg, 6d (Figure S3.10 Supporting Information). Pymol modeling suggests 
that this residue side chain may face the solvent rather than the enzyme making this 
location amenable for donor fluorophore attachment (Figure S3.6 Supporting 
Information).31   
 
 
Figure 3.1. Proteolytic cleavage of the quench probe. (left) The quench probe with the donor situated 
in the middle of the substrate sequence. (right) The quench probe with the donor situated between 
the substrate sequence and inhibitor sequence. 
	  
Results from proteolytic cleavage assays show that the quench probe with the 
donor in the middle of the substrate undergoes greater proteolytic cleavage than the probe 
with the donor between the substrate and inhibitor as evidenced by the larger increase in 
fluorescence (Figure 3.1). Although, post assay HPLC analysis indicates that both probes 
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are cleaved between the phenylalanine and alanine. The discrepancy in the proteolysis of 
the substrate portions of the probes is likely due to differences in where the scissile bond 
fits across the active site in relation to the α-helix fitting into the prime side cleft. The 
extra amino acid between the substrate sequence and α-helix may cause the scissile bond 
to not fit properly at the active site cysteine residue. The preferred sequence, K(Dabcyl)-
Pro-Leu-Phe-Ala-Glu(Edans)-Arg, is also desirable as the Pro-Leu-Phe-Ala-Ala-Arg 
substrate sequence is also cleaved by cathepsin L. 
Finally, we used the calpain mutations previously identified to create a more 
potent inhibitor post proteolytic cleavage. We synthesized quench probe peptides with the 
preferred substrate sequence, Lys(Dabcyl)-Pro-Leu-Phe-Ala-Glu(Edans)-Arg, and three 
different inhibitor sequences, the 3c inhibitor sequence (6d), the 
Propentafluorophenylalanine mutation (6e), and the LysArg mutation (6f). We then 
tested all quench probe peptides and the commercially available substrate in a proteolytic 
cleavage assay (Figure 3.2, Table S3.10 Supporting Information).  
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Figure 3.2. Quench probe and commercial substrate cleavage by calpain-1, cathepsin L, and 
cathepsin B. 
 
We found that both quench probes 6d and 6e have similar fluorescence increases 
while quench probe 6f has about half the fluorescence increase (Figure 3.2). This lack of 
fluorescence increase is likely due to an impurity in the purified product where there 
appeared to be a moiety with a double linker attachment that could not be separated from 
the single linker peptide. This impurity decreases the cleavable concentration. 
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Furthermore, it could be interacting with the enzyme. Satisfyingly, though, none of the 
quench probes are cleaved by cathepsin L or cathepsin B. 
For inhibition analysis the quench probes were synthesized without the 
donor/quencher fluorophores and tested against calpain-1, cathepsin L, and cathepsin B. 
Peptide 6g, Pro-Leu-Phe-Ala-Glu-Arg-Ile-Pro-Pro-Lys-Tyr-Cys-Glu-Leu-Leu-Cys, and 
peptide 6h, Pro-Leu-Phe-Ala-Glu-Arg-Ile-pfF-Pro-Lys-Tyr-Cys-Glu-Leu-Leu-Cys, had 
the same potency as their respective original inhibitors (Table 3.4, Figure S3.7 and Table 
S3.10 Supporting Information). Peptide 6h is also extremely specific for calpain-1 over 
both cathepsin L and cathepsin B. Peptide 6i, Pro-Leu-Phe-Ala-Glu-Arg-Ile-Pro-Pro-Arg-
Tyr-Cys-Glu-Leu-Leu-Cys, had a decrease in potency (Table 3.4, Figure S3.7 and Table 
S3.10 Supporting Information). Similar to the double mutant, 4c, the decrease in potency 
could be associated with a change in orientation of the helix due to the arginine mutation 
that further changes how the substrate sits across the active site. 
 Inhibitor Calpain Cathepsin L Cathepsin B 
6a PLFAERIPPKYCELLC 11.4 ± 3.7 6.4 ± 1.3 65.2 ± 1.3 
6b PLFAERIpfFPKYCELLC 5.6 ± 2.1  48.6 ± 1.2 64.7 ± 1.4 
6c PLFAERIPPRYCELLC 16.9 ± 5.5 17.0 ± 1.2 >100 
pfF=pentafluorophenylalanine 
Table 3.4 Quench Probes as Inhibitors. The Ki for each quench probe (without fluorophores) against 
canonical cysteine proteases. 
	  
3.3 Conclusion 
Alanine scanning mutagenesis identified two residues that are important for 
inhibitor binding to calpain-1 and two residues that could be mutated to enhance potency. 
Structure based design allowed us to propose mutations to increase potency, peptides 4a 
and 4b. Each of the proposed mutations resulted in an increase in potency. Further 
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analysis into lengthening the inhibitor demonstrated that additions to the N-terminus can 
increase potency. Finally, each aspect culminated in the development of a potent quench 
probe, 6h, that is only cleaved by calpain-1 and specifically inhibits calpain-1, not 
cathepsin L or cathepsin B.  
3.4 Materials and Methods 
3.4.1 Crosslinking with the unpurified peptide:  
The lyophilized crude peptide was dissolved in DMF (conc~1-5 mM) with 2% 
triethylamine. The alkylating agent, α,α’-dibromo-m-xylene (1.5 eq.), was added to the 
solution and shaken for the 2 h. The crude mixture was purified via HPLC. 
3.4.2 Protease Activity Assays:  
Peptides were evaluated for ability to inhibit cysteine proteases using standard 
proteolytic fluorescence activity assays. Inhibition was assayed using a standard donor-
quencher strategy with previously published peptide substrates.62,140,141  
Enzyme concentration for Calpain-1 was 25 nM. Enzyme concentration for 
cathepsin B and L was 3 nM, and cathepsin S was 5 nM. Calpain buffer contained 10 
mM dithiothreitol (DTT), 100 mM KCl, 2 mM EGTA, 50 mM Tris-HCl (pH 7.5), and 
0.015% Brij-35. Substrate concentration for calpain-1 was 0.5 µM NH2-Glu(Edans)-Pro-
Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH.62,140,141 Final substrate concentration for the 
cathepsins was 0.5 µM Z-FR-Amc. Cathepsin L buffer contained 10 mM DTT, 500 mM 
sodium acetate (pH 5.5), and 4 mM EGTA.62,140,141 Cathepsin B buffer contained 10 mM 
DTT, 100 mM sodium acetate (pH 5.5), 0.01% Triton X-100, and 4 mM EGTA. 
Cathepsin S buffer contains 10 mM DTT, 100 mM potassium phosphate (pH 6.5), and 4 
mM EGTA. Calpain was activated by the injection of CaCl2 to a final concentration of 5 
mM. Cathepsin assays were activated by the injection of the substrate to a final 
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concentration of 0.5 µM. Varying concentrations of inhibitor, 1-100 µM, were used for 
each assay. All assays were done at a total well volume of 100 µL in 96-well plate, and 
each well contained a separate inhibitor concentration. Fluorescence was read in a 
Berthold Tri-Star fluorimeter. The excitation wavelength was 380 nm and the emission 
wavelength was 500 nm for NH2-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-
OH. The excitation wavelength 351 nm and emission wavelength was 430 nm for Z-FR-
Amc. 
3.4.3 Protease Cleavage Assays:  
Protease cleavage assays were performed under the same buffer conditions per 
enzyme as the protease activity assays. Calpain concentration was 150 nM. Cathepsin B 
and L concentrations were 54 nM. Quench probe and substrate concentrations were 5 
µM. Calpain was activated via CaCl2 injection to a final concentration of 5 mM. Quench 
probe was added to active cathepsins just before fluorescence readings were taken. 
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CHAPTER 4: Development of Non-covalent, α-Helical Inhibitors of 
Cathepsins L, S, and K by Mimicking a Natural Protein-Protein 
Interaction 
 
4.1 Introduction: 
 
The human genome expresses 11 cathepsins that belong to the papain cysteine 
protease family (clan CA, family C1).125 Cathepsins are involved in normal cellular 
processes such as endosomal/lysosomal protein turnover125, bone remodeling, 
immunity29, apoptosis, and prohormone processing and in various disease states including 
viral invasion148,149, tumor growth, cancer tumor invasion16,150,151, angiogenesis16,151, 
rheumatoid arthritis14, and osteoporosis18,152. 
Due to their involvement in various diseases, cathepsins have become attractive 
targets for drug development. Previous efforts to develop specific inhibitors of cathepsins 
have been focused on small molecules, both covalent-irreversible26 and covalent-
reversible16,153, most of which bind to the unprimed side of the active site. One of the 
greatest issues with these inhibitors is the difficulty in the development of specificity to 
differentiate amongst the various closely related cysteine cathepsins. This is mainly due 
to the high conservation in the unprimed binding pockets of the papain superfamily active 
site.125,154,155 Additionally, most of the inhibitors developed to date covalently modify the 
cysteine residue via an electrophilic warhead group, which in turn also reduces the 
potential for specificity. Herein we set out to develop a set of specific, non-covalent 
inhibitors that utilize an α-helix-based scaffold for inhibition of three canonical members 
of the cathepsin L subfamily: cathepsin L, S, and K. 
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4.2 Results and Discussion: 
Cathepsins are composed of three domains: a signal peptide, prodomain, also 
known as the propeptide, and the catalytic domain.3,11,29,156 We were interested in 
utilizing the prodomain as a scaffold since it acts as potent, reversible inhibitor of its 
cognate enzyme.9,157,158 Each prodomain contains three α-helices wherein one α-helix 
occupies a binding site within the prime side of the active site along with a beta strand 
that further occludes substrate entry (Figure 4.1). The entire prodomain, including this α-
helix, binds to the active site cleft in the reverse direction of a normal peptide substrate to 
eliminate proteolytic cleavage. Every α-helix has a unique sequence that creates specific 
interactions with its respective enzyme, suggesting that these α-helices could be used to 
create specific inhibitors. Additionally, creating inhibitors that bind to the prime side of 
the protease active site opens up new avenues to explore for therapeutic development. 
Previously, an α-helical inhibitor for the cysteine protease calpain was developed 
using a structure-based design approach.159 This inhibitor was modeled after an α-helix in 
calpastatin, the endogenous proteinaceous inhibitor of calpain that binds across several 
domains within calpain, but makes one specific α-helical interaction within the prime 
side of the calpain active site. We hypothesized that we could similarly develop α-helix 
derived specific and potent inhibitors based on the prodomains of cathepsins that inhibit 
the enzymes via non-covalent binding to the prime side of the protease active site. 
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Figure 4.1: A-C) Zymogen crystal structures with the α-helix prodomain highlighted in the prime 
side of three different Cathepsins.31 A) Cathepsin L; sequence:  SEEFRQVMNGF; pdb: 1CS83,156. B) 
Cathepsin S; sequence: TSEEVMNSLMSS; pdb: 2C0Y29. C) Cathepsin K; sequence: 
SEEVVQKMTGL; pdb: 1BY811. Colored areas on the enzyme depict areas for enhancing peptide-
enzyme interactions. Orange designates active site, blue designates hydrophobic surfaces, pockets, 
and amino acids, and the dotted line designates helix linker. D) Schematic of α-helix stabilization via 
attachment of dibromo-m-xylene linker to cysteine side chain.31,159 
 
Each cathepsin L, S, and K zymogen crystal structure was examined to identify 
the prime-side prodomain α-helix of interest (Figure 4.1, A-C). The α-helices from these 
prodomains were synthesized (7a, 8a, and 9a) using standard solid-phase peptide 
synthesis and analyzed for inhibitory activity and secondary structure (Tables 4.1-4.3; 
Figures S4.1-4.3, S4.10, and S4.23 Supporting Information). Peptides 7a, 8a, and 9a 
showed no inhibition of their cognate enzymes and were primarily random coil in 
solution,7,73,159 presumably due to the inability of these short peptides to overcome the 
free energy barrier needed to form an α-helix. To address this issue, these short peptides 
were conformationally restricted to enhance α-helicity, using a protocol previously 
developed by the Greenbaum laboratory (Figure 4.1).159 This stabilization technique 
involves reacting the side chains of two cysteine residues in i, i+4 positions with a 
A. B. C.
D.
Cathepsin L: SEEFRQVMNGF Cathepsin S: TSEEVMSLMSS Cathepsin K: SEEVVQKMTGL
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dibromo-m-xylene linker. A series of paired cysteines to be used for stabilization were 
introduced into the peptide scaffold at positions that, from visual inspection of the 
zymogen crystal structure, would appear not to disrupt key protein-helix interactions. 
Several stabilized peptides were synthesized and screened for inhibition of cathepsin 
activity using a standard fluorescence-based protease activity assay (Tables 4.1-4.3, 
Figures S4.3-S4.35 Supporting Information). The development of a potent and selective 
inhibitor lead for each target cathepsin is discussed in detail below.  
 
4.2.1 Design of an α-helical Cathepsin L Inhibitor  
Starting with the native sequence of the cathepsin L prodomain α-helix (7a), 
peptides 7b and 7c were mutated with two cysteines spaced i, i+4 within the parent 
sequence. These two cysteines were then crosslinked using a dibromo-m-xylene linker. 
cathepsin L was inhibited by 7b and 7c with a Ki of 84.7 µM and 29.4 µM, respectively 
(Table 4.1, Figures S4.3-S4.5 Supporting Information). Peptide 7b displayed weak 
inhibition, possibly due to a steric clash between the linker and the enzyme. In the case of 
7c, the linker seems to be completely solvent exposed and unlikely to interact with the 
enzyme, resulting in better inhibition. These results indicate that the location of the linker 
can influence not only the helicity of the peptide, but also the inhibitory properties of the 
peptides. 
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Inhibitor 
Cathepsin K 
(µM) 
Cathepsin L 
(µM) 
Cathepsin S 
(µM) 
Calpain-1  
(µM) 
7a SEEFRQVMNGF NT 133.1 ± 1.4 NT NT 
7b SECFRQCMNGF NT 83.1 ± 1.2 NT NT 
7c SCEFRCVMNGF NI 29.4 ± 1.1 92.3 ± 1.2 NI 
7d SCEnRCVMNGF 102.2 ± 1.4 6.1 ± 1.0 20.2 ± 1.1 NI  
7e SCEbRCVMNGF NI 3.4 ± 1.0 43.1 ± 2.0 100.7 ± 31.3 
7f SCEFRCVMNGn 64.3 ± 12.5 6.7 ± 1.0 48.1 ± 1.2 NI 
7g SCEbRCVMNGn 32.0 ± 1.2 0.3 ± 1.2 27.4 ± 1.4 19.8 ± 6.3 
Linked cysteines are bolded and underlined, mutated residues are italicized; NT=Not Tested; NI= Not Inhibited; n= Ala(2-
naphthyl); b= Ala(4,4’-biphenyl) 
Table 4.1: Cathepsin L inhibitor potency and selectivity.  
 
Following optimization of the linker placement (7c), a structure-based approach 
was used to improve the potency and selectivity of the peptides. The prime side of the 
cathepsin L active site, where the relevant prodomain α-helix primarily binds, has one 
hydrophobic area: a shallow but wider surface near the canonical S3’ binding site (Figure 
4.1A).3 The unprimed side of the cathepsin L active site also has a hydrophobic area: a 
narrow cleft proximal to the active cysteine around the S2 binding site.3,158 The 
hydrophobic residues Leu69, Ala135, and Ala214 line the narrow cleft, while the shallow 
wider surface is comprised of Phe145, Phe143, Leu144, and Trp189. Based on the 
zymogen crystal structure the first Phe4 (relative to the N-terminus) in 7c would be 
predicted to occupy the narrow cleft, while Phe11 in 7c most likely is involved in π-π 
interactions with Trp189 and only partially occupies the hydrophobic surface. Hence, 
replacement of these residues with non-natural amino acid residues with a larger 
hydrophobic side chain might create a stronger hydrophobic interaction and in turn 
greater affinity of the inhibitor for the enzyme.  
	  
	   56	  
With this in mind, peptides 7d and 7e were synthesized, replacing Phe4 with 
Ala(2-naphthyl) and Ala(4,4’-biphenyl), respectively. As anticipated, both substitutions 
demonstrated increased inhibition of cathepsin L: the Ala(2-naphthyl) mutation resulted 
in a Ki~6 µM while the Ala(4,4’-biphenyl) mutation resulted in a Ki~3 µM (Table 4.1, 
Figures S4.6 and S4.7 Supporting Information). Interestingly, the biphenyl mutation 
resulted in a more specific inhibitor than the Ala(2-naphthyl) mutation. It can be 
postulated that the biphenyl offers an extended hydrophobic surface as well as some 
flexibility due to possible rotation between the two phenyl rings avoiding unfavorable 
steric clashes. Phe11 was mutated to Ala(2-naphthyl), 7f. For the C-terminal 
modification, Ala(4,4’-biphenyl) was not considered because it would extend the peptide 
too far into the unprimed side possibly reducing specificity. This C-terminal Ala(2-
naphthyl) mutation resulted in a Ki~6.7 µM (Table 4.1, Figure S4.8 Supporting 
Information). Combining the mutations from 7e and 7f resulted in an additive effect with 
the double mutant peptide 7g showing a Ki against cathepsin L of ~300 nM that was at 
least 66 times more specific for cathepsin L over other enzymes (Table 4.1, Figure S4.9 
Supporting Information). These results demonstrate that the prime side interactions are 
sufficiently different to allow us to create potent and highly specific cathepsin L 
inhibitors. 
 
4.2.2 Design of an α-helical Cathepsin S Inhibitor 
The cathepsin S inhibitor was designed similarly to the cathepsin L inhibitor. The 
putative α-helix scaffold 8a was mutated to incorporate paired cysteines and then 
stabilized159; 8b was stabilized closer to the N-terminus and 8c was stabilized closer to 
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the C-terminus. Only inhibitor 8c increased inhibition (Table 4.2, Figures S4.10-S4.12 
Supporting Information). One hypothesis for the lack of potency of 8b is that the m-
xylene linker that stabilizes the α-helix creates a steric clash between the peptide and the 
enzyme (Figure 4.1B). 
 Inhibitor Cathepsin K 
(µM) 
Cathepsin L 
(µM) 
Cathepsin S 
(µM) 
Calpain-1 
(µM) 
8a TSEEVMSLMSS NT NT 101.6 ± 1.5 NT 
8b TCEEVCSLMSS NT NT 184.6 ± 1.1 NT 
8c TSEEVCSLMCS NI 16.7 ± 2.6 52.1 ± 1.1 33.4 ± 10.3 
8d WSEEVCSLMCS NI 76.0 ± 1.2 51.0 ± 1.2 108.4 ± 1.2 
8e TWEEVCSLMCS 67.5 ± 1.2 93.9 ± 1.3 29.7 ± 1.1 NI 
8f TSEWVCSLMCS NI 57.1 ± 1.2 33.1 ± 1.1 NI 
8g TSEEWCSLMCS NI >100 80.4 ± 1.2 NI 
8h TWEWVCSLMCS 65.7 ± 1.5 33.8 ± 1.2 14.3 ± 1.1 88.4 ± 1.1 
8i TnEnVCSLMCS 62.9 ± 1.2 2.4 ± 1.3 12.9 ± 1.1 97.3 ± 1.4 
8j WWEWVCSLMCS 19.5 ± 1.2 16.1 ± 1.4 6.7 ± 1.1 85.5 ± 1.3 
8k WWEWWCSLMCS 37.9 ± 1.4 28.1 ± 1.1 1.1 ± 1.1 66.7 ± 1.2 
8l FFEFFCSLMCS NT NT 13.1 ± 1.1 NT 
8m WWEWbCSLMCS NT NT 9.7 ± 1.0 NT 
Linked cysteines are bolded and underlined, mutated residues are italicized. NT=Not Tested; NI=Not Inhibited; 
n=Ala(2-naphthyl); b=Ala(4,4’-biphenyl) 
Table 4.2: Cathepsin S inhibitor potency and selectivity data.  
 
Stabilized peptide 8c inhibited cathepsin S with a modest Ki of ~54 µM (Table 
4.2). Interestingly, 8c was much more potent for cathepsin L over cathepsin S, but did not 
inhibit cathepsin K (Table 4.2). The cathepsin L activity could be attributed to the 
similarity in charge and polarity of the amino acid residues at the N-terminus of the 
stabilized parent peptides of cathepsin L and cathepsin S. Intriguingly, the area of the 
enzyme in proximity to the polar N-terminus of the α-helix (8a) is a large hydrophobic 
surface lined by residues Tyr117, Phe245, Trp285, and Phe289. Phe245 and Trp285 also 
comprise part of the S1’ subsite where the parent peptide Met binds.29 Therefore, 
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introducing hydrophobic residues into the N-terminus of the cathepsin S inhibitor would 
not only increase binding but also may increase specificity for cathepsin S over cathepsin 
L and cathepsin K since both these enzymes have a much smaller and more localized 
hydrophobic surface. Four of the five N-terminal residues were thus mutated to 
tryptophan beginning with single mutants (Table 4.2, Figures S4.13-S4.16 Supporting 
Information). The tryptophans in the first and second positions are likely binding to novel 
prime side sites.29 The tryptophan residues at the fourth and fifth positions are most likely 
partially binding to the residues lining the S1’ subsite as well as the novel hydrophobic 
surface. The single mutant studies demonstrated that changing any one of the N-terminal 
residues to tryptophan generally increased the peptides’ affinity for cathepsin S (Table 
4.2). The glutamate was not mutated because this residue appears to be involved in 
hydrogen bonding interactions with the enzyme via bridging water molecules.  
Based on these findings, double, triple, or quadruple tryptophan mutants were 
synthesized using the hypothesis that adding multiple hydrophobic amino acid residues 
might increase the potency of the inhibitor, due to this presence of the much larger 
hydrophobic surface near the active site of cathepsin S. Two double mutants were 
synthesized, a double tryptophan mutant, 8h, and a double Ala(2-naphthyl) mutant, 8i. 
The tryptophan is largely hydrophobic, but it also has the ability to hydrogen bond 
directly or through water molecules using the indole ring. Both double mutants showed 
the same potency profile, suggesting that the hydrophobic interactions are the primary 
mode of binding at the N-terminus (Table 4.2, Figure S4.17 and S4.18 Supporting 
Information). The specificity profile for the two mutants was different though, with 8h 
being more selective for cathepsin S than 8i (Table 4.2). The tryptophan double mutant 
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8h, showed a Ki~14µM, and the specificity profile remained the same as 8c (Table 4.2). 
The triple mutant 8j further enhanced the inhibitory activity (Ki~7µM) (Table 4.2, Figure 
S4.19 Supporting Information). Finally, the quadruple mutant 8k inhibited cathepsin S 
with a Ki~1.23µM and was 30-60-fold more selective for cathepsin S over other enzymes 
(Table 4.2, Figure S.4.20 Supporting Information). A quadruple phenylalanine mutant, 8l, 
further emphasized the role of the hydrophobic interactions as phenylalanine has a 
smaller surface area, and subsequently creates weaker hydrophobic interactions thereby 
resulting in a less potent inhibitor (Table 4.2, Figure S4.21 Supporting Information).  
 
4.2.3 Design of an α-helical Cathepsin K Inhibitor  
Like cathepsin L and S, the unstabilized, native α-helix derived from the 
prodomain of cathepsin K demonstrated no inhibition of cathepsin K. After visual 
inspection of the zymogen structure, only one location seemed appropriate for side chain 
stabilization, peptide 9b (Figure 4.1C). Unfortunately this inhibitor was not as potent as 
the other stabilized parent α-helical inhibitors (Table 4.3, Figures S4.23 and S4.24 
Supporting Information).  
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 Peptide Cathepsin K 
(µM) 
Cathepsin L 
(µM) 
Cathepsin S 
(µM) 
Calpain-1 
(µM) 
9a SEEVVQKMTGL NI NT NT NT 
9b SCEVVCKMTGL 196.9 ± 1.6 NI 255.3 ± 1.6 NI 
9c SCESVCKMTGL 3.8 ± 1.1 116.9 ± 2.7  10.8 ± 1.0 217.6 ± 1.8 
9d SCEHVCKMTGL 15.7 ± 1.1 NT NT NT 
9e SCENVCKMTGL 78.8 ± 1.3 NT NT NT 
9f SCELVCKMTGL 19.0 ± 1.1 NT NT NT 
9g SCEVVCKPTGL 4.4 + 1.1 48.0 ± 1.20 58.3 ± 1.2 147.9 ± 1.5 
9h SCEVVCKMWGL 2.9 ± 1.0 16.8 ± 1.2 50.0 ± 1.0 37.1 ± 11.6 
9i SCEVVCKMFGL 10.2 ± 1.2 NT NT NT 
9j SCEVVCKMTGP 4.9 ± 1.1 53.9 ± 1.2 27.8 ± 1.5 NI 
9k SCESVCKMTGP 20.3 ± 1.2 NT NT NT 
9l SCEVVCKPTGP 39.8 ± 1.1 NT NT NT 
9m SCESVCKPWGP 16.0 ± 1.1 143.0 ± 1.4 375.0 ± 1.8 102.3 ± 1.6 
Linked cysteines are bolded and underlined, mutated residues are italicized; NT=Not Tested; NI=Not inhibited  
Table 4.3: Cathepsin K inhibitor potency and selectivity data. 
 
To optimize electrostatic interactions with Gln242 on the enzyme surface, the Val 
was mutated to Ser, 9c, His, 9d, Asp, 9e, or Leu, 9f (Table 4.3 Figures S4.25-4.28 
Supporting Information). Peptide 9c (Ki~3.8 ± 1.1 µM) was by far the most potent 
peptide out of the mutants suggesting that perhaps there was a hydrogen bond forming at 
that location (Table 4.3).  
In the zymogen crystal structure, the cathepsin K α-helix is terminated at the 
Met75 in the P2’ position followed by a curve around the active site (Figure 4.3). 
Subsequently, the C-terminus (the last four amino acids) of peptide 9g is unstructured in 
solution. It was hypothesized that replacing Met with Pro, a constrained amino acid, 
would provide some structure to the C-terminus to reduce binding energy as well as 
terminate the α-helix and enhance the curve around the active site. Inhibitor 9g resulted 
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in an inhibitor with a Ki value of 4.4 µM, suggesting that Pro works as a constraint (Table 
4.3, Figure S4.29 Supporting Information).  
Other single mutations were a Thr to Trp mutation, 9h, and Thr to Phe mutation, 
9i. Peptides 9h and 9i were designed to fit the respective tryptophan or phenylalanine into 
the S1’ subsite.11 The tryptophan could still form electrostatic interactions with Gln260 
while also giving the possibility of forming a π-π interaction with the catalytic histidine. 
The phenylalanine could possibly only form π-π interaction with histidine. Peptide 9h 
had a Ki~2.9 compared to 9i which had a Ki~10.2 µM suggesting that π-π interactions as 
well as hydrogen bonding interactions are important (Table 4.3, Figures S4.30 and S4.31 
Supporting Information). 
It has been suggested that Pro is an optimal amino acid to bind to the S2 pocket of 
cathepsin K.11,160 Thus we synthesized an inhibitor with a Leu to Pro mutation at the C-
terminus, 9j. The proline in the P2 position should be specific to cathepsin K, as it has 
been suggested that cathepsins S and L do not tolerate proline well at this position.161 
Inhibitor 9j inhibited cathepsin K at a Ki~4 µM (Table 4.3, Figure S4.32 Supporting 
Information).   
Double mutants 9k and 9l and quadruple mutant 9m were synthesized to explore 
the effects of combining the single mutations. Unlike the inhibitors of the other enzymes 
the multiple mutants reduced the effectiveness of the inhibitor (Table 4.3, Figures S4.33-
S4.35 Supporting Information). These results could stem from each single mutation 
slightly adjusting how the inhibitor fits into the prime side of the active site thereby 
changing the effect of the other mutation. 
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Each single mutant had a substantial inhibitory effect on cathepsin K. Peptide 9h 
was the most potent inhibitor, while 9g was almost as potent but about 10 fold more 
specific for cathepsin K over the all other enzymes. Thus, we were again able to create 
potent and specific leads for inhibitor development using rational structure-based design. 
 
4.2.4 Peptide Characterization and Kinetics 
After testing the inhibitory activity of the inhibitors, the peptides’ helical 
character and the mode of inhibition were determined. First, circular dichroism analysis 
(CD) was used to characterize α-helicity. As expected, the parent peptides 7a, 8a, and 9a 
showed some helical character but were primarily random coil as evidenced by a 
minimum closer to 200 nm rather than at 208 and 222 nm.117 CD analysis of the linked 
peptides 7c, 8c, and 9b showed an increased helical character upon stabilization (Figures 
S4.1 and S4.2 Supporting Information) as a decrease in the minimum at 222 nm and a 
shift in minimum to 208 nm from 200 nm. Thus the more helical the peptide, the more 
potent inhibitor, which supports the theory that the free energy needed for secondary 
structure formation is a substantial barrier to inhibitory activity of small, unstabilized 
peptides. Beyond the increase of helical character, it was clear that hydrophobic and π-
π stacking interactions could further optimize inhibitor potency and specificity. Finally, 
standard Michaelis-Menten kinetics confirmed that all inhibitors acted in a competitive 
manner (Figure S4.36, Tables S4.2-S4.4 Supporting Information). 
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4.3 Conclusion: 
We have used a structure-guided approach to develop competitive, non-covalent, 
α-helical inhibitors for cathepsins L, S, and K by mimicking their prodomain active site 
α-helices. We were able to generate inhibitor leads for each class of enzymes with good 
selectivity and moderate potency using only a small set of compounds. This proof-of-
concept study provides the basis for the future optimization of more potent and specific 
inhibitors of cathepsins. 
 
4.4 Materials and Methods: 
4.4.1 Crosslinking with the unpurified peptide:  
The lyophilized crude peptide was dissolved in DMF with 2% triethylamine.  The 
alkylating agent (app. 3 eq) was added to the solution and shaken for the 2 h.  The crude 
mixture was purified by HPLC. 
4.4.2 Protease Activity Assays:  
Peptides were evaluated for ability to bind and subsequently inhibit the cysteine 
proteases using standard proteolytic fluorescence activity assays. Inhibition was assayed 
using a standard donor quencher strategy using a previously published peptide 
substrates62,140,141.  
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CHAPTER 5: Future Directions 
 
Structure-based design has allowed us to create potent and specific inhibitors for 
papain family cysteine proteases. We have further used our knowledge of structure, 
endogenous inhibitor binding, and substrate specificity to increase the potency and 
specificity of each inhibitor. These inhibitors have thus become the basis for activity 
based probe and quench activity based probe development.  
5.1 Incorporation of Cell Penetrating Peptides to Increase Cell Permeability 
One of the issues faced during the development of these α-helical inhibitors and 
probes is the lack of cell penetrability. Cell permeability can be improved through the 
addition of cell penetrating peptides or CPPs. Cell penetrating peptides are generally 
derivatives of proteins that translocate cargo through the cellular membrane.162,163 The 
parent proteins are often found in viruses or antimicrobial peptides.162,163 CPPs can be 
amphipathic or polypositive. Amphipathic CPPs are generally α-helical with a positively 
charged face and a hydrophobic face. Polypositive CPPs are usually unstructured 
peptides with multiple arginines and/or lysines.162,163 Cell penetrating peptides have been 
suggested to enter the cell via either endocytsosis, the method of entry of many of the 
virus derived CPPs, or via direct permeation, the suggested method of entry for 
polyarginine CPPs and amphipathic CPPs.164  
CPPs have been successfully added to a calpastatin derivative, a 27 amino acid 
calpain inhibitor, to enhance cell permeability. One such CPP is penetratin.62 Penetratin is 
a 7 or 16 amino acid derivative of the antennapedia homeodomain from Drosophila.62,165 
Penetrating was attached to the calpastatin derivative via a disulfide bond. The calpastatin 
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based inhibitor was then able to translocate through the cell membrane, localize to the 
cytoplasm, resulting in the inhibition of calpain-1.62 
To increase cell penetration by the quench probes we propose the addition of 9-
arginines, the 7 amino acid penetratin, or the CPP low molecular weight protamine or 
LMWP (a 14 amino acid derivative of protamine, a protein that binds DNA).162,166 These 
peptides were chosen for their presumed ability to transport cargo to the cytoplasm rather 
than the lysosome or nucleus. For polyarginine CPPs it has been suggested that there is a 
threshold above which direct permeation is the predominate mode of entry as opposed to 
endocytsosis.164 Amphipathic CPPs were avoided because they tend to have α-helical 
secondary structures and an additional α-helix may disrupt binding of the inhibitor to the 
enzyme.  
For calpain inhibitors and probes the cell penetrating peptides would be added to 
the N-terminus of the quench probe In the crystal structure the portion of the calpastatin 
that binds to calpain domain-3 appears to mostly form backbone interactions with the 
enzyme rather than side chain interactions.30,69 Furthermore, this portion of calpastatin 
also does not have many conserved residues (among the four calpastatin domains) 
making the sequence amenable to amino acid changes.30,69 Furthermore, Betts et al. 
demonstrated that changing these residues to β-alanine did not affect the potency of the 
27-mer calpastatin suggesting again that this region can be easily mutated with few 
adverse effects on potency.123 
The cell penetrating ability of the probes can be tested in both a canonical HeLa 
cell line as well as a mouse embryo fibroblast (mEF) line that has both a wild type (WT) 
and calpain small subunit (CAPNS1-/-) constitutive knockout lines. The CAPNS1-/- line 
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allows for an additional negative control regarding the inhibitors/probes binding to active 
calpains. Enzymes can be manually activated using calcium ionophore. These cell studies 
will give us an idea as to how useful the inhibitors/probes will be in actual disease 
models. 
5.2 Development of Cathepsin Probes 
The small peptidic α-helical inhibitor of calpain was turned into an activity based 
probe through the addition of a warhead or substrate sequence and a tag, a fluorophore or 
biotin. The small α-helical prodomain based inhibitors developed for each individual 
cathepsin can also be models for activity based probe development. Similarly to 
calpastatin, these inhibitors will only bind to active enzymes because the prodomain in 
the inactive enzyme would sterically prevent the inhibitor/probe from binding to the 
enzyme.  
The cathepsin inhibitor sits in the reverse direction of the substrate meaning that 
the C-terminus faces the unprimed side of the enzyme while the N-terminus faces the 
prime side. Based on the crystal structure models the N-terminus of these inhibitors is 
solvent exposed and not interacting with the enzyme. Thus the tag can be added via a 
peptide bond to the N-terminus of the inhibitor. Adding the tag to the N-terminus 
eliminates the necessity of having an alloc protected lysine or the cost of buying an 
amino acid with a biotin or fluorophore already attached. The development of these 
probes would help isolate the individual protease is involved in each respective disease.  
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5.3 α-helical Inhibitors for Other Classes of Proteases 
We have primarily focused on designing α-helical inhibitors and probes for 
cysteine proteases, however we believe this inhibitory motif can be expanded to include 
other classes of proteases. 
Thrombin is an enzyme involved in the clotting of blood, subsequently it is of 
great pharmaceutical interest as specific inhibitors of thrombin could be good 
anticoagulants.167 When the insect the mosquito takes a blood meal it injects an enzyme 
called anophelin into the site of the blood draw to prevent clotting.168 Interestingly, based 
on the crystal structure, it appears that anophelin binds to thrombin in the same way 
calpastatin binds to calpain. Anophelin is unstructured in solution and has a slow tight 
binding mechanism in which the inhibitor binds to the enzyme in the same N to C 
orientation as the substrate.168 Anophelin also forms an α-helix at the active site just like 
calpain.168,169 
 
Figure 5.1: Active site α-helices of the calpain bound calpastatin (left) and the thrombin bound 
anophelin (right). Insets show the enzymes in their entirety. (Calpain: 3BOW; Thrombin: 
4E06).30,31,168  
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Rather than appearing as a classical two-turn α-helix like in calpastatin, it appears 
that anophelin has a single α-helical turn followed by a β-turn. However, it is possible 
that either the single α-helical turn or the β-turn could be stabilized by the linker. 
Furthermore, from the information gathered during the calpain inhibitor stabilization 
studies it appears that a single proline near the stabilization site can result in a stable loop 
which could be a useful mutation in this inhibitor to stabilize the β-turn.   
Development of inhibitors such as this could be quite useful as a scaffold for the 
development of new anticlotting therapeutics. 
5.4 Concerns 
Stabilized α-helices as inhibitors have previously successful as inhibitors of 
protein-protein interactions.44 The advantage of these α-helical peptide inhibitors has 
been their increased specificity and potency due to the large number of inhibitor-protein 
contacts and the ability to interact with a large surface area. Furthermore, the stabilization 
of these peptides has reduced the entropic penalty of binding to the enzyme and in many 
cases also increased the cell permeability and proteolytic stability. Thus the inhibitors and 
probes that we have developed have the potential to begin a completely new class of tools 
for investigation into protease role in cell processes and disease. 
The use of stabilized α-helices as protease inhibitors does have some drawbacks, 
though. We are targeting proteases, so we are deliberately sending the peptides to areas of 
high protease activity thereby increasing the potential for degradation. Furthermore, the 
protease inhibitors we have designed are stabilized in an i, i+4 conformation leaving the 
unstabilized portion of the inhibitor open to proteolysis. With these weaknesses in mind, 
cytoplasmic or extracellular proteases such as calpain-1 are probably the best targets for 
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the α-helical peptidic inhibitors as proteases in these locations are generally tightly 
regulated which reduces the likelihood of proteolysis. However, the work we have done 
on the cathepsin inhibitors is not in waste as we can use the knowledge we gained to 
synthesize non-peptidic inhibitors that exploit the same enzymatic binding sites as the α-
helical inhibitors. 
Another concern with the α-helical protease inhibitors was the lack of cell 
permeability of these peptides. This problem can be addressed through the use of other 
stabilization methods, like those discussed in the introduction (Chapter 1.5) which have 
been shown to possibly increase cell permeability, or through the use of cell penetrating 
peptides (Chapter 5.1).170  
Finally, α-helical protease inhibitors and probes are likely most useful in the 
laboratory setting for the investigation of the role these cysteine proteases play in cell 
processes and disease models. However, the knowledge gained through the development 
and use of these probes may be helpful for creating small molecule inhibitors or 
therapeutics in the future.  
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APPENDIX  
	  
Abbreviations 
	  
ABP  activity based probe 
β  Ala(4,4’-biphenyl) 
βA  β-alanine 
βP  β-proline 
CAPNS1-/- calpain-1 small subunit knockout 
CD  circular dichroism 
CPP  cell penetrating peptide 
DCM  dichloromethane 
DIPEA diisopropylethylamine 
DMF  α,α’-dimethylformamide 
DMSO  dimethyl sulfoxide 
DTT  dithiothreitol 
EDT  1,2-ethanedithiol 
EGTA  ethylene glycol tetraacetic acid 
ESI  electrospray ionization 
FITC  fluorescein isothiocyanate 
HBTU O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HCl  hydrochloric acid 
HCTU O-(1H-6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HPLC  high pressure liquid chromatography 
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HRP  horseradish peroxidase 
IC50  concentration at which 50% of the enzyme is inhibited 
INFIT  inverse Fourier transformation of in-phase multiplets 
Ki  inhibition constant 
Km  Michaelis constant 
MALDI-TOF matrix-assisted laser desorption/ionization-time of flight 
mEF  mouse embryo fibroblast 
Mmt  methoxytrityl 
MS  mass spectrometer 
N  Ala(2-naphthyl) 
NMP  N-methylpyrrolidone 
NMR  nuclear magnetic resonance 
PDB  protein database 
pfF  pentafluorophenylalanine 
PVDF  polyvinyl difluoride 
RCM  ring closing metathesis 
RFU  relative fluorescence units 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TCEP  tris(2-carboxyethyl)phosphine 
TFA  trifluoroacetic acid 
TFE  trifluoroethanol 
TIPS  triisopropylsilane 
Trt  trityl 
WT  wild type 
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Chapter 2 Supporting Information 
	  
General Information  
Amino acids were purchased from Advanced ChemTech(Louisville, KY) or 
Chem-Impex (Wood Dale, IL). Biotinylated lysine was purchased from Anaspec 
(Freemont, CA). All crosslinkers and the enzyme papain were purchased from Sigma-
Aldrich® (St. Louis, MO). Chemicals were purchased from Fisher Scientific (Pittsburgh, 
PA). Calpain-1 and cathepsin B were purchased from BioVision (Milpitas, CA). 
Cathepsin L was purchased from EMD Millipore (Billerica, MA). Substrates were 
purchased from Peptides International (Louisville, KY). Single fritted reservoirs for 
peptide synthesis were purchase from Biotage (Redwood City, CA). Film for imaging 
blots was purchased from Kodak (Rochester, NY). Bis-Tris NuPAGE® gels and a 
Novex® Colloidal Blue Staining Kit were purchased from Life Technologies (Grand 
Island, NY). A Vectastain® Elite® ABC kit for biotin blotting was purchased from Vector 
Laboratories (Burlingame, CA). A Bio-Rad Silver Stain Plus Kit was purchased from 
Bio-Rad (Hercules, CA). Peptides were synthesized on an Argonaut QuestTM 210 
(Argonaut Technologies, Inc. now owned by Biotage, Redwood City, CA) or on a 
Symphony automated peptide synthesizer (Protein Technologies, Inc., Tuscon, AZ). 
Peptides were purified on an Agilent 1100 Series LC/MS or an Agilent 1200 Series 
LC/MS  (Agilent Technologies, Inc., Santa Clara, CA) Hewlett Packard ChemStation 
software using a Vydac® C8 column (Grace, Deerfield) or a Zorbax XDB-C18 column 
(Agilent Technologies, Inc., Santa Clara, CA). Matrix assisted laser desorption/ionization 
time of flight (MALDI-TOF) mass spectra were obtained using a Bruker Ultraflex III 
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mass spectrometer (Billerica, MA). Electrospray ionization (ESI) mass spectra were 
obtained with a QTRAP® 3200 (AB SCIEX, Framingham, MA). Circular dichroism (CD) 
spectra were obtained with a JASCO J-810 spectropolarimeter (JASCO, Inc., Easton, 
MD) equipped with a Peltier temperature control unit. NMR spectra were obtained using 
a Bruker Avance III 500 MHz spectrometer equipped with a cryogenic probe (Billerica, 
MA). UV-Vis absorbance spectra were obtained using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Wilmington, DE). Fluorescence spectra were 
collected with a Berthold Tri-Star multimode microplate reader (Berthold Technologies, 
GmbH & Co. KG, Bad Wildbad, Germany). Gels were visualized with a Typhoon 
Fluorescent Imager (GE Healthcare Biosciences, Pittsburgh, PA). Graphing was 
performed using GraphPad Prism (GraphPad Software, La Jolla, CA). 
	  
	   74	  
Synthetic procedure 
General peptide synthesis: All peptides were synthesized at 0.1 or 0.2 mmol 
scales using Chemmatrix Rinkamide Resin (substitution: 0.52 mmol/g) or CLEARTM 
Amide resin (substitution: 0.46 mmol/g). Fmoc-protected amino acids (5-fold excess) 
were activated with 0.95 equivalents (relative to the amino acid) of HBTU in the 
presence of 10 equivalents of diisopropyethanolamine (DIPEA). Amino acids were 
coupled for 5 min at 65 oC in DMF (Quest synthesis) or 25 min at room temperature in 
DMF (Symphony synthesis). Fmoc deprotection was performed using 20% 4-methyl 
piperidine in DMF for 5 min at 65 oC (Quest Synthesis) or 2.5 min (x 2) at room 
temperature (Symphony Synthesis).   Side chain deprotection and the simultaneous 
cleavage from the resin were carried out using a mixture of 
TFA/thioanisole/ethanedithiol/anisole (90:5:3:2, v/v) at room temperature, for 2.5 hours. 
The crude peptide was precipitated using cold diethyl ether and purified via reverse-phase 
chromatography with a C8 preparative column using buffer A (0.1% TFA in Millipore 
water) and buffer B’ (0.1% TFA in 60% iso-propanol/30% acetonitrile /10% Millipore 
water). Initial HPLC conditions were 5% B’/95% A. Initial conditions were run for 5 
min, followed by an increase of solution B’ to 100% at 25 min (5%/min.) at a flow rate of 
5 ml/min unless otherwise indicated. The mass of all peptides was verified by MALDI-
TOF or ESI-MS and purity (greater than 95%) was checked by analytical HPLC.  
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 Sequence Calcd 
m/z 
Obsvd 
m/z 
HPLC-
Gradient 
Retention 
Time 
(min) 
Model 
Peptide 
Ac-YGGEAAREACARECAARE-
NH2171 
1954.4 1954.1 0-100% 13.3 
(C4 Vydac column over a gradient 0% to 100% of acetonitrile in water (0.1% TFA) over 40 minutes) 
Table S2.1. Calculated and observed model peptide masses. 
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Crosslinker Screening Procedure   
Preparation of stock solution: A peptide solution (0.114 mM) in NH4HCO3 
buffer (12mL, 50 mM, pH=8.0) was treated with TCEP (1M solution in the same 
NH4HCO3 buffer, 1.1 eq.) at room temperature for 1 h.42,105,172 The concentration of the 
peptide solution was measured by A280= 1280 M-1cm-1 or by a weight based method 
(molecular weight was adjusted by adding one TFA salt per basic residue and by adding 
10% (of the calculated molecular weight) to account for hydration after lyophilization). 
Crosslinking procedure in 96-well plate: 90 µL of the stock solution was added 
to each well of a black round-bottomed 96-well plate (polypropylene). 10 µL of the 
freshly prepared alkylating agent solution (1.5 mM in anhydrous DMF, 1.5 eq.) was 
added to each well at room temperature and stirred for 2 h while protected from light. 
MALDI analysis was done to see the reaction progress and more alkylating agent was 
added if needed. Addition of 5% HCl to each well neutralized and subsequently quenched 
the reaction. 100 µL of diethyl ether was added to the organic layer to remove excess 
alkylating agent. The ether layer was removed by pipetting and MALDI-TOF spectra 
were taken of the sample in the remaining aqueous solution mixture.  
	  
	   77	  
 
High concentration of Reactants (for “selection of the fittest” reaction)  
Preparation of stock solution: A peptide solution (1.2 mM) in Tris-HCl buffer 
(100 mM, pH=8.0) was treated with TCEP (1M solution in the Tris-HCl buffer, 1.1 eq.) 
at room temperature for 1 h. The concentration of the peptide solution was measured by 
A280= 1280 M-1cm-1 or by a weight based method (molecular weight was adjusted by 
adding one TFA salt per basic residue and by adding 10% (of the calculated molecular 
weight) to account for hydration after lyophilization). 
Crosslinking procedure in 1.5 mL centrifuge tube: This procedure is slightly 
modified from the procedure in Materials and Methods. 450 µL of the stock solution of 
peptide was added to a 1.5 mL polypropylene microcentrifuge tube. 50 µL of the freshly 
prepared alkylating agent solution (225 mM in anhydrous DMSO, app. 20 eq.) was added 
to each well at room temperature and the turbid mixture was shaken for 2 h under 
protection from light. The reaction was quenched by neutralization through the addition 
of 0.6 N HCl (10 µL) into each well. Each tube was centrifuged to remove the insoluble 
material and the supernatant was either purified by HPLC analysis or lyophilized. 
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* 1919.84 appeared to be elimination of thiol from the cysteine. 
Figure S2.1. MALDI spectra of low concentration linker with the model peptide. 
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Without Crosslinker 
 
 
Reaction with crosslinker c14 
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Reaction with crosslinker c15 
 
 
Reaction with crosslinker c16 
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Reaction with crosslinker c17 
 
 
Reaction with crosslinker c18 
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Reaction with crosslinker c19 
 
 
Reaction with crosslinker c20 
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Reaction with crosslinker c21 
 
 
Reaction with crosslinker c22 
 
	  
	   85	  
Reaction with crosslinker c23 
 
 
Reaction with crosslinker c24 
 
Figure S2.2 Crude HPLC profile  (Low Concentration Reaction with the model peptide). 
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* denotes the major monocyclization product 
Figure S2.3. Crude HPLC profile – “selection of the fittest” reaction 
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NMR spectroscopy 
The peptide sample was prepared using peptide concentrations of 2 mM in 0.6 mL 
of a 9:1 v/v water/D2O mixture in 50mM sodium phosphate, pH 5.5. All spectra were 
recorded at 10 oC on a Bruker Avance III 500 MHz spectrometer equipped with a 
cryogenic probe. 
All 2D homonuclear spectra were recorded with standard pulse sequences173. 2D 
NOESY experiments were carried out with mixing times of 150 ms and 250 ms, 
respectively, 5483 Hz on both t1 and t2 dimensions with t1,max = 93 ms and t2,max = 183 ms, 
32 scans. 2D TOCSY experiments were carried out with a mixing time of 75 ms, 5000 
Hz on both t1 and t2 dimensions with t1,max = 93 ms and t2,max = 205 ms. 2D DQF-COSY 
experiments were carried out with 5000 Hz on both t1 and t2 dimensions with t1,max = 120 
ms and t2,max = 205 ms. The 1H carrier frequency was always set to the water peak and 
chemical shifts were referenced with respect to the residual water peak at 4.90 ppm. 
Spectra were processed and analyzed using the programs nmrPipe174 and 
XEASY175, respectively. Time domain data were multiplied by sine square bell window 
functions shifted by 60o and zero-filled once.  
Using DQF-COSY, TOCSY, and NOESY sequence specific assignments were 
obtained following standard procedures173.  
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A. 
 
B. 
 
 Figure S2.4. Characterization of helix formation in the peptide by NMR spectroscopy. A) Secondary 
chemical shifts of α-H as a function of residue. B) Chemical shift index (CSI) output as a function of 
residue. Both strongly demonstrate helix formation even in the fraying terminus. 
α-H chemical shifts have a strong relationship to protein secondary structures176. 
Secondary chemical shifts are calculated by subtracting the experimental values from the 
intrinsic values. Secondary chemical shifts indicate that all 18 residues show helix 
formation in the peptide. Output from Chemical Shift Index (CSI) 176,177 clearly shows 
that 83% (15 out of 18) residues form helical structures. Two of the three non-helical 
residues are terminal residues.  The third non-helical residue is the helix breaker glycine.
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Alanine Scanning Mutagenesis  
To identify the hot spot residues that are important to the protein-peptide 
interaction, the molecular modeling software package Rosetta178 was used to calculate the 
binding free energy changes upon alanine mutation of each residue. The hot spots are 
defined as the residues that have changes in the binding free energy more than 1 kcal/mol 
when mutating to alanine (∆∆G value).179 Modeling was begun with the 3BOW.pdb 
crystal structure. The target sequence was threaded into the backbone, namely 
E622K(204), H625E(207) and D628A(210), and then the whole peptide was repacked as 
the starting structure. Alanine scanning was performed for each residue sequentially and 
the ∆∆G value was calculated as show in table S2.2. 
Residue Chain ID Mutation ∆∆G (kcal/mol) 
207 C EA -0.1 
206 C RA 0.0 
210 C AA 0.0 
211 C NA 0.1 
201 C IA 0.3 
204 C KA 0.4 
203 C PA 0.5 
202 C PA 1.1 
205 C YA 1.5 
209 C LA 1.7 
208 C LA 1.9 
Table S2.2. Alanine Scanning Mutagenesis, 
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Synthesis of calpain inhibitors 
Calpain inhibitors were synthesized via solid phase peptide synthesis in the same 
manner as the model peptide. Helical calpain inhibitors were stabilized using the α,α’-
dibromo-m-xylene crosslinker c15 and the “low concentration” linking protocol. 
Peptide No. Sequence Calcd 
(m/z) 
Obsvd 
(m/z) 
HPLC-
Gradient 
Retention 
Time 
(min) 
Parent Ac-IPPKYRELLA-NH2 1240.5 1240.5 0-100% 6.91 
3a Ac-IPCKYRCLLA-NH2 1220.6 1220.5 0-100% 6.85 
3b Ac-IPPCYRECLA-NH2 1205.5 1205.3 0-100% 7.60 
3c Ac-IPPKYCELLC-NH2 1219.6 1219.4 0-100% 8.30 
3a Ac-IPCKYRCLLA-NH2 1322.6 1322.6 0-100% 7.99 
3b Ac-IPPCYRECLA-NH2 1307.5 1307.5 0-100% 8.60 
3c Ac-IPPKYCELLC-NH2 1321.6 1321.5 0-100% 9.83 
Table S2.3. Uncrosslinked and crosslinked calpastatin fragment peptides. 3a-c are all m-xylyl crosslinked. 
Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over a gradient of acetonitrile 
in water (0.1% HCOOH) over 20 minutes. 
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CD Spectra of Calpain Inhibitors without TFE 
Peptide solutions were prepared at ~100 µM in 50 mM Tris-HCl (pH 7.5) without 
TFE. Concentrations were determined by measuring tyrosine absorbance at 276 nm with 
an extinction coefficient of 1400 M-1 cm-1. Scans were conducted from 260 nm to 200 
nm.113,117,180 Measurements were conducted at 20°C in 1 nm step mode with a response 
time of 4 seconds in a 1 mm path length quartz cuvette. 
	  
Figure S2.5. CD spectrum of uncrosslinked peptide 3a-c in Tris buffer (50mM, pH=7.5). 
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Figure S2.6. CD spectrum of crosslinked peptide 3a-c in Tris buffer (50mM, pH=7.5). 
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Protease Activity Assays 
All peptides were evaluated for ability to bind and subsequently inhibit the 
cysteine protease calpain using standard proteolytic fluorescence activity assays. 
Inhibition was assayed using a standard donor-quencher strategy using a previously 
published calpain peptide substrate.62,140,141  
Calpain Assay: Enzyme concentration for calpain-1 was 25 nM. The buffer 
contained 10 mM dithiothreitol (DTT), 100 mM KCl, 2 mM EGTA, 50 mM Tris-HCl 
(pH 7.5), and 0.015% Brij-35. Substrate concentration was 0.25 µM H-Glu(Edans)-Pro-
Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH.62,140,141 Varying concentrations of inhibitor, 0, 
0.5, 1, 2, 5, 7, 10, 15, 25, 50, and 100 µM, were used for each assay. Positive controls 
contained no inhibitor and negative controls contained no calcium. Enzyme, buffer, 
substrate, and inhibitor (or DMSO in controls) were combined. Calpain was activated by 
the injection of CaCl2 to a final concentration of 5 mM. All assays were done in triplicate 
at a total well volume of 100 µL in 96-well plate, and each well contained a separate 
inhibitor concentration. Fluorescence readings were taken every 13 seconds for one hour 
in a fluorescent plate reader. Excitation wavelength was 380 nm and the emission 
wavelength was 500 nm. 
Papain Assay: Enzyme concentration for papain was 25 nM. The buffer 
contained 10 mM dithiothreitol (DTT), 100 mM KCl, 2 mM DGTA, 50 mM Tris-HCl 
(pH 7.5), 0.015% Brij-35. Substrate concentration was 10 µM H-Glu(Edans)-Pro-Leu-
Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH.62,140,141 Varying concentrations of inhibitor, 0, 0.5, 1, 
2, 5, 7, 10, 15, 25, 50, and 100 µM, were used for each assay. Buffer, papain, and 
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inhibitor were all combined first. The assay was initiated by the addition of substrate via 
a multichannel pipette. All assays were done at a total well volume of 100 µL in 96-well 
plate, and each well contained a separate inhibitor concentration. Fluorescence readings 
were taken every 13 seconds for one hour in fluorescent plate reader. The excitation 
wavelength was 380 nm and the emission wavelength was 500 nm. 
Cathepsin Assay: Enzyme concentration for cathepsin B and cathepsin L was 3 
nM.  The buffer contained 10 mM DTT, 500 mM sodium acetate (pH 5.5), and 4 mM 
EGTA, and 0.015% Brij-35.62,140,141 Substrate concentration for both enzymes was 0.25 
µM Z-FR-Amc. 0, 0.5, 1, 2, 5, 7, 10, 15, 25, 50, and 100 µM, were used for each assay. 
Buffer, enzyme, and inhibitor were combined. Cathepsin assays were activated by the 
addition of substrate via a multichannel pipette. All assays were done at a total well 
volume of 100 µL in 96-well plate, and each well contained a separate inhibitor 
concentration. Fluorescence readings were taken every 13 seconds for one hour in 
fluorescent plate reader. The excitation wavelength was 351 nm and emission wavelength 
was 430 nm.  
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Figure S2.7. Representative calpain activity assay progress curve. Progress curves were truncated at 
~500 seconds. After 500 seconds the progress curve loses linearity due autoproteolysis of the enzyme. 
181 Data collected after curvature began was not used in any calculations. 
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Km Determination for calpain substrate 
We calculated the Km for the NH2-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-
Lys(Dabcyl)-OH substrate when cleaved by calpain using standard Michaelis-Menten 
kinetics.142 We identified the initial velocity of calpain at substrate concentrations, 1, 3, 5, 
10, 20, and 30 µM. Velocities were determined in RFU/sec then converted to µM/sec 
using the conversion factor 1386 RFU/µM. The conversion factor was obtained by the 
total hydrolysis of the substrate NH2-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-
Lys(Dabcyl)-OH in a known concentration by papain. We then plotted velocity vs. 
substrate concentration and used GraphPad Prism program Michaelis-Menten (under 
kinetics) to determine the Km. At high concentrations, >10 µM, of substrate the inner 
filter effect, whereby free quencher absorbed the fluorescence emission of the cleaved 
fluorophore, became evident. To take this quenching into consideration, the velocity at 
each substrate concentration was multiplied by the corresponding correction factor: 
Corr%=fEDANS (at each substrate concentration)/fEDANS (in the absence of substrate).182  
 
Figure S2.8. Michaelis-Menten curve for determining Km of calpain substrate. 
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Figure S2.9. IC50 Curves for enzyme assays. Ki was calculated from IC50 using the equation: 
.124,142 The inhibitor was tested against purified human calpain-1. The Km used for the 
calpain Ki determination was 4.66 µM.  
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Kinetic analysis of Calpain-1 by 3c 
To identify inhibition type we used standard Michaelis-Menten treatment. Initial 
velocities were calculated from the linear segment of the progress curves then plotted 
against their substrate concentration.142 Due to the linearity of the first segment of the 
progress curve we believe that autoproteolysis during the first 500 seconds was not 
substantial enough to prevent the use of simple Michaelis-Menten kinetics, i.e. loss of 
enzyme did not change the velocity enough to cause it to deviate from linearity and 
incorporation of this additional complex would severely complicate the kinetics. 
Velocities were determined in RFU/sec then converted to µM/sec using the conversion 
factor 1386 RFU/µM. The conversion factor was obtained by the total hydrolysis of the 
substrate NH2-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-Lys(Dabcyl)-OH in a known 
concentration by papain. 
	  
Figure S2.10. Michaelis-Menten plot of initial velocities at different substrate and inhibitor 
concentrations.  
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 [3c]  (µM) Vmaxapp  (µM/sec) Kmapp 
0 0.0029 ± 0.0003 4.66 ± 1.08 
1 0.0029 ± 0.0002 6.47 ± 0.95 
3 0.0029 ± 0.0003 7.40 ± 1.63 
5 0.0028 ± 0.0003 8.11 ± 1.96 
10 0.0030 ± 0.0004 11.35 ± 3.76 
Table S2.4. Vmaxapp and Kmapp values obtained from the above Michaelis-Menten plot.  
 
Vmaxapp is the same at all inhibitor concentrations while Kmapp increases with 
increasing inhibitor concentration. These results are indicative of competitive inhibition. 
To avoid weighting errors we used the values of Kmapp and Vmaxapp determined directly 
from the non-linear least-squares best fits of the untransformed data and put these values 
into the reciprocal equation: 
€ 
1
v
= ( Km
Vmax
×
1
[S]
) + 1
Vmax
.142 
We then plotted the resulting reciprocal velocities against the respective 
reciprocal substrate concentrations. 
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Figure S11. IC50 Curves for enzyme assays using inhibitor 3c. Ki was calculated from IC50 using the 
equation: 
€ 
Ki =
IC50
1+ [S]
Km
.124,142,183  
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Calpain Activity Based Probe Synthesis 
All probes were synthesized by standard solid phase synthesis techniques using 
single fritted reservoir on Rink Amide resin (0.59 mmol/g substitution). Activation of 
Fmoc-amino acids (5-fold excess) was achieved with O-(1H-6-chlorobenzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium hexafluorophosphate (HCTU) in the presence of DIPEA. 
The reaction solvent contains 100% N,N-dimethylforamide (DMF) (HPLC grade, 
Fisher). The epoxysuccinic acid was synthesized according to a procedure reported in the 
literature.184 The epoxysuccinic acid was added using the same coupling procedure as the 
amino acids.  
Biotin tag addition was done using biotinylated lysine in the peptide synthesis 
process. Fluorescein isothiocyantate (FITC) tag was added post cleavage to the crude 
peptides. FITC addition was performed post-cleavage by adding 1 eq. fluorescein 
isothiocyanate and 10 eq. DIPEA to the peptide dissolved in DMF and stirred under 
argon for 1 hr. For FITC labeled probe an allyloxycarbonyl (alloc) protected lysine was 
used for the non-tagged lysine. The alloc was removed using 1 eq. tetrakis(triphenyl 
phosphine)palladium(0) with 10 eq. 5,5-dimethyl-1,3-cyclohexane dione stirred for 2 hr.  
Deprotection of side chains and cleavage of peptides from amide resin: Side 
chain deprotection and simultaneous cleavage from the resin were carried out using a 
mixture of trifluoroacetic acid (TFA)/triisopropylsilane (TIPS)/water (90:5:5, v/v) at 
room temperature, for 3 hours. Crude peptide was obtained by ether precipitation and 
purified by reverse-phase chromatography. The mass of all peptides was verified by ESI-
MS.  
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 Sequence Calcd  
(m/z) 
Obsvd 
(m/z) 
HPLC- 
Gradient 
Retention 
Time (min) 
NM-01-
biotin 
Epoxide-
AAIPPKYCELLCK-
biotin 
1890.29 1890.1 0-100% 9.864 
NM-02-
biotin 
Epoxide-
βAAIPPKYCELLCK-
biotin 
1890.29 1890.1 0-100% 10.085 
NM-03-
biotin 
Epoxide-
AβPIPPKYCELLCK-
biotin 
1928.92 1928.2 0-100% 10.137 
NM-02-
FITC 
Epoxide-
βAAIPPKYCELLCK-
FITC 
2033.84 
1016.92 
(M/2) 
1016.5 
(M/2) 
0-100% 8.655 
Table S2.5. Calculated and Observed Masses for Calpain Activity Based Probes. 
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Enzyme Labeling Experiments 
For enzyme labeling experiments a greater concentration of enzyme was used 
than for the kinetic experiments for visualization of the enzyme of gel stains. 
Calpain Probe Linker Experiments 
Experimental conditions included 10 mM dithiothreitol (DTT), 1.5 µg Calpain, 
100 mM KCl, 2 mM EGTA, 50 mM Tris-HCl (pH 7.5), 0.015% Brij-35, and either 1 µM 
or 10 µM of biotinylated probe (DCG-04 (positive control), NM-01, NM-02, NM-
03).62,140,141 Calpain was activated by the addition of calcium (3.33 µM of 50 mM CaCl2) 
to a final concentration of 8.3 mM. The negative control contained water instead of 
CaCl2, in a calpain solution with 10 µM probe. Probes were allowed to bind to the 
calpain for 20 minutes at room temperature. The reaction was stopped by the addition of 
10 µL NuPage® LDS Running Buffer. 10 µL of each labeling experiment was loaded on 
a 10% Bis-Tris NuPAGE® gel for 1.5 hrs, 140 V. The bands were then transferred to a 
PVDF membrane at 30 V for 70 min. The membrane was blocked with casein and blotted 
for biotin. Film was exposed for 1 hr. and developed.   
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Calpain Labeling experiments 
Experimental conditions were 10 µM dithioreitol (DTT), 1.5 µg Calpain-1 or 6 
µM Calpain-2 (the calpain-2 was not as active), 100 mM KCl, 2 mM EGTA, 50 mM 
Tris-HCl (pH 7.5), 0.015% Brij-35, and 1, 2.5, 5, 10, or 20 µM of FITC-labeled NM-02, 
or 2 µM DCG-04.62,140,141 Calpain was activated by the addition of calcium (3.33 µM of 
50 mM CaCl2) to a final concentration of 8.3 mM. The negative control was unactivated 
calpain tube containing 10 µM probe where water was added instead of calcium. Probes 
were allowed to bind to the calpain for 20 minutes at room temperature. The reaction was 
stopped by the addition of 10 µL NuPage® LDS Running Buffer. 10 µL of each 
condition was loaded on a 10% Bis-Tris NuPAGE® gel for 1.5 hrs at 140 V. The gel was 
visualized on a Typhoon Fluorescent Imager. Following scanning the gel was stained 
with a Novex® Colloidal Blue Staining Kit. 
Papain Labeling experiments 
Experimental conditions were 10 µM dithioreitol (DTT), 1.5 µg Papain, 100 mM 
KCl, 2 mM EGTA, 50 mM Tris-HCl (pH 7.5), 0.015% Brij-35, and 1, 2.5, 5, or 10 µM of 
FITC-labeled NM-02, or 2 mM DCG-04.62,140,141 Probes were allowed to bind to the 
papain for 20 minutes at room temperature. The reaction was stopped by the addition of 
10 µL NuPage® LDS Running Buffer. 10 µL of each condition was loaded on a 10% 
Bis-Tris NuPAGE® gel for 1.5 hrs at 140 V. The gel was evaluated on a Typhoon 
Fluorescent Imager. Following scanning the gel was stained to verify loading with a Bio-
Rad Silver Stain Plus Kit. 
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Cathepsin Labeling experiments 
Experimental conditions were 10 µM dithioreitol (DTT), 1.5 µg Cathepsin B or 
Cathepsin L, 500 mM sodium acetate, 4 mM EGTA, (pH 5.5), and 1, 2.5, 5, or 10 µM of 
FITC-labeled NM-02, or 2 mM DCG-04.62,140,141 Probes were allowed to bind to the 
enzymes for 20 minutes at room temperature. The reaction was stopped by the addition of 
10 µL NuPage® LDS Running Buffer. 10 µL of each condition was loaded on a 12% 
Bis-Tris NuPAGE® gel for 1.5 hrs., 140 V. The gel was evaluated on a Typhoon 
Fluorescent Imager. Following scanning the gel was stained to verify loading with a Bio-
Rad Silver Stain Plus Kit. 
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Chapter 3 Supporting Information 
 
Alanine Scanning Mutagenesis 
Alanine scanning is a technique in which each respective residue in a peptide is 
sequentially mutated to alanine to identify how important that residue is for inhibition. 
Peptide  
No. 
Sequence Calcd  
m/z 
Obsvd  
m/z 
HPLC-
Gradient 
Retention 
Time (min) 
3c IPPKYCELLC 1320.6 1321.6 1-100% 9.67 
3d APPKYCELLC 1278.6 1279.6 1-100% 8.20 
3e IAPKYCELLC 1294.6 1296.5 1-100% 9.25 
3f IPAKYCELLC 1293.6 1294.2 1-100% 6.13 
3g IPPAYCELLC 1263.5 1264.5 1-100% 12.48 
3h IPPKACELLC 1228.6 1229.4 1-100% 9.07 
3i IPPKYCALLC 1262.6 1263.4 1-100% 8.83 
3j IPPKYCEALC 1278.6 1279.4 1-100% 8.98 
3k IPPKYCELAC 1278.6 1279.3 1-100% 8.89 
(Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over a gradient of acetonitrile in water 
(0.1% HCOOH over 20 minutes.) Cysteines that are bold and underlined are linked residues.  
Table S3.1. Calculated and observed masses of crosslinked inhibitors with alanine mutations. 
 
 Inhibitor 
Calpain-1 
(µM) 
Cathepsin L 
(µM) 
Cathepsin S 
(µM) 
3c IPPKYCELLC 10.2 ± 2.9 39.9 ± 1.1 50.2 ± 1.2 
3d APPKYCELLC 65.6 ± 20.5 12.5 ± 1.2 26.1 ± 1.3 
3e IAPKYCELLC 13.7 ± 4.4 0.6 ± 1.4 13.1 ± 1.11 
3f IPAKYCELLC 27.4 ± 8.6 NT NT 
3g IPPAYCELLC 17.7 ± 5.6 24.6 ± 1.2 20.7 ± 1.2 
3h IPPKACELLC >100 8.1 ± 1.2 16.8 ± 1.1 
3i IPPKYCALLC 28.9 ± 9.1 12.5 ± 1.1 15.6 ± 1.6 
3j IPPKYCEALC 30.9 ± 9.2 21.4 ± 1.2 13.9 ± 1.0 
3k IPPKYCELAC 25.2 ± 7.9 19.7 ± 1.1 15.2 ± 1.1 
Cysteines that are bold and underlined are linked residues.  
Table S3.2. Ki determination of alanine mutated crosslinked inhibitors against cysteine proteases.  
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Figure S3.1. IC50 curves of alanine mutants against cysteine proteases.   
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Calpain Inhibitor Mutants 
Isoleucine and tyrosine were mutated to other polar, nonpolar, and extended side 
chain amino acids to investigate the role the specific side chain played in inhibition. 
Peptide No. Sequence Calcd 
m/z 
Obsvd 
m/z 
HPLC-
Gradient 
Retention 
Time (min) 
3m LPPKYCELLC 1320.6 1321.5 1-100% 8.92 
3n QPPKYCELLC 1335.6 1336.6 1-100% 8.66 
3o IPPKbCELLC 1381.5 1382.5 1-100% 11.57 
3p IPPKbzlYCELLC 1410.5 1411.6 1-100% 11.98 
(Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over a gradient of acetonitrile in water 
(0.1% HCOOH over 20 minutes.). Cysteines that are bold and underlined are linked residues. b=Ala(4,4’-biphenyl); 
bzlY=O-benzyl tyrosine 
Table S3.3. Calculated and observed masses of calpain-1 inhibitor mutants. 
 
  Inhibitor 
Calpain-1  
(µM) 
Cathepsin L 
(µM) 
Cathepsin S 
(µM) 
3m LPPKYCELLC 10.96 ± 3.6 38.1 ± 1.2 46.3 ± 1.2 
3n QPPKYCELLC 35.02 ± 10.4 NT NT 
3o IPPKbCELLC 9.65 ± 3.2 1.9 ± 1.1 1.4 ± 1.1 
3p IPPKbzlYCELLC 21.26 ± 6.7 16.7 ± 1.3 3.3 ± 1.2 
Cysteines that are bold and underlined are linked residues.  b=Ala(4,4’-biphenyl); bzlY=O-benzyl tyrosine 
Table S3.4. Ki of calpain-1 mutant inhibitors. Isoleucine was mutated to various polar and nonpolar 
residues. Tyrosine was mutated to various resides to determine if extending the side chain would enhance 
calpain binding.  
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Figure S3.2. IC50 curves of calpain-1 inhibitors with isoleucine mutated to various polar and 
nonpolar residues. 
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Single and Double Mutants Determined by Alanine Scanning Mutagenesis and 
Structure Based Design 
Alanine scanning mutagenesis identified two residues in the ten amino acid 
calpain-1 inhibitor that were not essential for inhibition, and subsequently were amenable 
to mutation. Structure based design was then used to pick amino acids that would 
enhance proposed binding interactions. Each individual single mutant resulted in 
increased inhibition, however the double mutant had reduced inhibition. 
Peptide No. Sequence Calcd 
m/z 
Obsvd 
m/z 
HPLC-
Gradient 
Retention 
Time (min) 
4a IpfFPKYCELLC 1410.6 1411.8 1-100% 13.10 
4b IPPRYCELLC 1348.6 1349.6 1-100% 9.50 
4c IpfFPRYCELLC 1488.6 1489.4 1-100% 10.77 
(Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over a gradient of acetonitrile in water 
(0.1% HCOOH over 20 minutes.). Cysteines that are bold and underlined are linked residues. b=Ala(4,4’-biphenyl); 
bzlY=O-benzyl tyrosine 
Table S3.5. Calculated and observed masses for single and double mutant calpain-1 inhibitors. 
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Figure S3.3. IC50 curves of single and double mutants of the mutable residues of the calpain-1 inhibitor. 
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Lengthened Peptide Inhibitors 
Calpain-1 inhibitors were extended using the activity based probe sequence and 
the endogenous calpastatin sequence to investigate how additional amino acids affected 
inhibitory activity. 
Peptide No. Sequence Calcd  
m/z 
Obsvd 
m/z 
HPLC-
Gradient 
Retention 
Time  
(min) 
5a βAAIPPKYCELLC 1462.7 1463.7 1-100% 9.02 
5b EVTIPPKYCELLC 1649.8 1650.7 1-100% 8.07 
5c LGKREVTIPPKYCELLC 2104.1 
1052.1 
(M/2) 
1053.5 1-100% 7.88 
5d LFKREVTIPPKYCELLC 2192.1 
1096.1 
(M/2) 
1097.6 1-100% 8.51 
5e EVTIPPKYCELLC 1547.8 1548.3 1-100% 9.38 
(Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over a gradient of acetonitrile in water 
(0.1% HCOOH over 20 minutes.). Cysteines that are bold and underlined are linked residues. 
Table S3.6. Calculated and observed masses for calpain-1 inhibitors of increasing length. 
	  
  Inhibitor 
Calpain-1 
(µM) 
Cathepsin L 
(µM) 
Cathepsin S 
(µM) 
5e EVTIPPKYCELLC 80.4 ± 25.0 NT NT 
Cysteines that are bold and underlined are linked residues.  NT=not tested 
Table S3.7. Ki of the unstabilized 13 amino acid calpain-1 inhibitor. 
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Figure S3.4.IC50 curves of lengthened calpain-1 inhibitors. 
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Quench Probe Development 
For the development of the quenched activity based probe numerous peptides 
were synthesized to address possible locations for the donor and quencher and identify 
the potency of inhibitors without the fluorophores. 
Peptide 
No. 
Sequence Calcd 
m/z 
Obsvd 
m/z 
HPLC-
Gradient 
Retention 
Time 
(min) 
6a PLFAARIPPKYCELLCK 2103.1 
1051.6.0 
(M/2) 
1052.6 1-100% 16.51 
6b IPPKYCELLCR 1476.7 1477.4 1-100% 8.50 
(Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over a gradient of acetonitrile in water 
(0.1% HCOOH over 20 minutes.). Cysteines that are bold and underlined are linked residues.  
Table S3.8. Calculated and observed masses for calpain-1 inhibitors with positive amino acid at C-
terminus. 
	  
  Inhibitor 
Calpain-1 
(µM) 
Cathepsin L 
(µM) 
Cathepsin S 
(µM) 
6a PLFAARIPPKYCELLCK 16.3 ± 5.2 5.2 ± 1.2 NT 
6b IPPKYCELLCR 47.6 ± 14.9 NT NT 
NT=not tested 
Table S3.9. Ki of calpain-1 inhibitor and probe that have a charged residue at the C-terminus for either 
fluorophore addition or cell permeability enhancement. 
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Figure S3.5. IC50 curves for calpain-1 inhibitors with C-terminal positively charged amino acids.  
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Peptide 
No. 
Sequence Calcd 
m/z 
Obsvd 
m/z 
HPLC 
Gradient 
Retention 
Time 
(min) 
6c K(Dabcyl)PLFAARE(Edans)IPPKYCELLC 2730.7 
1365.4 
(M/2) 
1366.5 1-100% 13.00 
6d K(Dabcyl)PLFAE(Edans)RIPPKYCELLC 2659.7 
1329.9 
(M/2) 
1331.0 1-100% 13.56 
6e K(Dabcyl)PLFAE(Edans)RIpfFPYCELLC 2699.7 
1349.8 
(M/2) 
1349.9 1-100% 14.42 
6f K(Dabcyl)PLFAE(Edans)RIPPRYCELLC 2687.7 
1343.8 
(M/2) 
1344.9 1-100% 13.57 
6g PLFAERIPPKYCELLC 2031.99 
1015.99 
(M/2) 
1017.2 1-100% 10.84 
6h PLFAERIpfFPKYCELLC 2072.0 
1036.0 
(M/2) 
1036.6 1-100% 11.37 
6i PLFAERIPPRYCELLC 2061.3 
1030.7 
(M/2) 
1031.7 1-100% 10.47 
(Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over a gradient of acetonitrile in water 
(0.1% HCOOH over 20 minutes.). Cysteines that are bold and underlined are linked residues.  
Table S3.10. Observed and calculated masses of quench probes and their respective inhibitors without the 
fluorophores.  
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Figure S3.6. Model of stabilized α-helical quench probe with the substrate sequence Pro-Leu-Phe-
Ala-Glu-Arg. The glutamate (circled in black) appears to be facing the solution making it a good 
candidate for fluorophore attachment.31 
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Figure S3.6. IC50 curves for quench probe inhibitors without fluorophores. 
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Chapter 4 Supporting Information 
	  
General Information 
Amino acids were purchased from Advanced ChemTech (Louisville, KY) or 
Chem-Impex (Wood Dale, IL). Chemicals were purchased from Fisher Scientific 
(Pittsburgh, PA). Calpain-1 was purchased from BioVision (Milpitas, CA). Cathepsin L 
was purchased from EMD Millipore (Billerica, MA). Cathepsin K and cathepsin S were 
purchased from Enzo Life Sciences (Farmingdale, NY). Substrate Z-FR-Amc was 
purchased from Peptides International (Louisville, KY), and substrate Z-VVR-Amc was 
purchase from Enzo Life Sciences (Farmingdale, NY). Single fritted reservoirs for 
peptide synthesis were purchase from Biotage (Redwood City, CA).  
Peptides were purified on an Agilent 1100 Series LC/MS or an Agilent 1200 
Series LC/MS (Agilent Technologies, Inc., Santa Clara, CA) Hewlett Packard 
ChemStation software using a Zorbax XDB-C18 column (Agilent Technologies, Inc., 
Santa Clara, CA). Matrix assisted laser desorption/ionization time of flight (MALDI-
TOF) mass spectra were obtained using a Bruker Ultraflex III mass spectrometer 
(Billerica, MA).  
Circular dichroism (CD) spectra were obtained with an AVIV spectropolarimeter 
(AVIV biomedical, Inc., Lakewood, MD) equipped with a temperature control unit. UV-
Vis absorbance spectra were obtained using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific, Wilmington, DE). Fluorescence spectra were collected with a 
Berthold Tri-Star multimode microplate reader (Berthold Technologies, GmbH & Co. 
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KG, Bad Wildbad, Germany). Graphing was performed using GraphPad Prism 
(GraphPad Software, La Jolla, CA). 
 
General peptide synthesis 
All peptides were synthesized at a scale of 0.1 mmol using Rink amide Resin 
(Chemimpex) (substitution: 0.52 mmol/g). Fmoc-protected amino acids (5-fold excess) 
were activated with 0.95 equivalents (relative to the amino acid) of HCTU in the 
presence of 5 equivalents of diisopropyethanolamine (DIPEA). Amino acids were 
coupled for 1 hr at room temperature. Fmoc deprotection was performed using 20% 4-
methyl piperidine in DMF for 30 min at room temperature. Side chain deprotection and 
the simultaneous cleavage from the resin were carried out using a mixture of 
TFA/triisopropylsilane (TIPS)/water (95:2.5:2.5, v/v) at room temperature, for 2.5 hours. 
The crude peptide was precipitated using cold diethyl ether. The ether was evaporated 
and then the crude peptide was dissolved in 50% water/50% acetonitrile and lyophilized. 
  
Crosslinker Addition 
The lyophilized crude peptide was dissolved in DMF and to it 1.5 eq. of 
alkylating agent, α,α’-dibromo-m-xylene was added. To the resulting solution 1.5 eq of 
triethylamine was added to initiate the reaction. The reaction mixture was allowed to 
react for 1 h under constant shaking.42,105,159,172 Reaction was monitored for completion 
by HPLC. 
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Purification of Peptides 
The linked peptide was purified via reverse-phase chromatography with a C18 
semi-preparative column using buffer A (0.1% TFA in 95% Millipore water/5% 
acetonitrile) and buffer B (0.1% TFA in 100% acetonitrile). Initial HPLC conditions were 
100% A. Initial conditions were run for 5 min, followed by an increase of solution B to 
100% at 30 min (4%/min.) at a flow rate of 4.18 ml/min. The mass of all peptides was 
verified by ESI-MS and purity (greater than 95%) was checked by analytical HPLC (0 to 
100% solution B over 20 min. at 1 mL/min.). 
 
Peptide 
No. 
Sequence Calcd 
m/z 
Obsvd 
m/z 
M+1 
HPLC 
Gradient 
(analytical) 
Retention Time 
(min) 
1a SEEFRQVMNGF 1383.6 1384.5 0-100% 8.90 
1b SECFRQCMNGF 1463.5 1464.1 0-100% 8.95 
1c SCEFRCVMNGF 1434.5 1435.7 0-100% 10.21 
1d SCEnRCVMNGF 1484.6 1485.5 0-100% 10.27 
1e SCEbRCVMNGF 1510.6 1511.4 0-100% 10.66 
1f SCEFRCVMNGn 1484.6 1485.5 0-100% 10.20 
1g SCEbRCVMNGn 1560.6 1561.4 0-100% 10.55 
2a TSEEVMSLMSS 1240.4 1241.3 0-100% 7.80 
2b TCEEVCSLMSS 1330.5 1331.6 0-100% 7.41 
2c TSEEVCSLMCS 1330.5 1331.4 0-100% 9.53 
2d WSEEVCSLMCS 1415.5 1416.3 0-100% 11.13 
2e TWEEVCSLMCS 1429.5 1430.5 0-100% 9.75 
2f TSEWVCSLMCS 1387.5 1488.2 0-100% 10.97 
2g TSEEWCSLMCS 1417.5 1418.2 0-100% 9.92 
2h TWEWVCSLMCS 1486.6 1487.4 0-100% 14.38 
2i TnEnVCSLMCS 1508.6 1509.3 0-100% 17.01 
2j WWEWVCSLMCS 1571.6 1572.3 0-100% 15.18 
2k WWEWWCSLMCS 1658.6 1659.7 0-100% 14.92 
2l FFEFFCSLMCS 1502.6 1503.5 0-100% 10.36 
2m WWEWbCSLMCS 1695.7 1696.5 0-100% 13.66 
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3a SEEVVQKMTGL 1261.6 1262.5 0-100% 7.42 
3b SCEVVCKMTGL 1311.6 1312.5 0-100% 9.04 
3c SCESVCKMTGL 1299.4 1300.3 0-100% 8.06 
3d SCEHVCKMTGL 1349.5 1350.5 0-100% 7.47 
3e SCENVCKMTGL 1326.5 1327.2 0-100% 7.80 
3f SCELVCKMTGL 1325.6 1326.5 0-100% 9.58 
3g SCEVVCKPTGL 1277.6 1278.3 0-100% 7.73 
3h SCEVVCKMWGL 1396.6 1397.4 0-100% 10.24 
3i SCEVVCKMFGL 1357.6 1358.3 0-100% 20.99 
3j SCEVVCKMTGP 1295.5 1296.4 0-100% 7.89 
3k SCESVCKMTGP 1283.5 1284.3 0-100% 7.28 
3l SCEVVCKPTGP 1261.5 1262.2 0-100% 8.42 
3m SCESVCKPWGP 1334.5 1335.5 0-100% 7.88 
Table S4.1: Calculated and observed inhibitor masses of parent peptides and prodomain fragment 
peptides. Prodomain fragment peptides 1b-1g, 2b-2m, and 3b-3m are all crosslinked with α ,α’-m-
dibromoxylyl crosslinker. Peptides were run on an Agilent LC-MS with an Eclipse XDB-C18 column over 
a gradient of acetonitrile in water (0.1% HCOOH) over 20 min. n=Ala(2-naphthyl); b=Ala(4,4’-biphenyl) 
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Circular Dichroism Spectra of Inhibitors  
We analyzed the unstabilized parent peptide and stabilized inhibitor peptides via 
circular dichroism (CD) data for in buffer without 40% trifluoroethanol (TFE).117,180 CD 
traces demonstrate that the unstabilized peptides are primarily random coil with an 
increase in helicity, to varying degrees, upon stabilization. In buffer the peptide 1g 
appears to be a loop in solution but likely helix formation occurs upon binding to the 
enzyme. Peptide 3g is mostly random coil in buffer likely due to the double proline, helix 
breaker, addition. 
Peptide solutions were prepared at ~50 µM in 100 mM potassium phosphate 
buffer (cathepsin L and K: pH=5.5, cathepsin S: pH=6.5). Concentrations were 
determined either by measuring aromatic absorbance at 280 nm or 254 nm or by mass. 
Scans were conducted from 260 nm to 200 nm.117,180,185 Measurements were conducted at 
25 ˚C in 1 nm step mode with a response time of 5 seconds in a 1 mm path length 
cuvette. 
 
Figure S4.1: A-C) Circular dichroism spectra of parent unstructured peptides and stabilized inhibitors of 
Cathepsin L (A), Cathepsin S (B), and Cathepsin K (C) in buffer with 40% TFE (100 mM potassium 
phosphate buffer, Cathepsin L and K: pH 5.5, Cathepsin S: pH=6.5).  
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Figure S4.2: Circular dichroism data of parent unstructured peptides and stabilized inhibitors of 
Cathepsin L (A), Cathepsin S (B), Cathepsin K (C) in buffer without TFE (100 mM potassium phosphate 
buffer, cathepsin L and K: pH=5.5, cathepsin S: pH=6.5).  
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Protease Activity Assays 
All peptides were evaluated for ability to inhibit the cysteine protease calpain 
using standard proteolytic fluorescence activity assays. Inhibition was assayed using a 
standard donor/quencher strategy with standard peptide substrates. 
Enzyme concentration for cathepsin L was 4 nM. Enzyme concentrations for 
cathepsins S and K are 5 nM. Enzyme concentration for Calpain-1 was 25 nM. Cathepsin 
K and L buffer contained 10 mM DTT, 200 mM sodium acetate (pH 5.5), 2 mM EGTA, 
and 0.01% Triton X-100 or 10 mM DTT, 500 mM sodium acetate (pH 5.5), and 4 mM 
EGTA.62,140,141,186,187 Cathepsin S buffer contained 10 mM DTT, 100 mM potassium 
phosphate, and 4 mM EGTA. Calpain buffer contained 10 mM dithiothreitol (DTT), 100 
mM KCl, 2 mM EGTA, 50 mM Tris-HCl (pH 7.5), and 0.015% Brij-35. Substrate 
concentration for calpain was 0.5 µM NH2-Glu(Edans)-Pro-Leu-Phe-Ala-Glu-Arg-
Lys(Dabcyl)-OH (Ex=380 nm, Em=500 nm).62,140,141 Substrate concentration for the 
cathepsins K and L was 0.5 µM Z-FR-Amc and for cathepsin S was 0.5 µM Z-VVR-Amc 
(Ex=351 nm, Em=430 nm).186-188 Inhibitor concentrations of 0, 0.5, 1, 2, 5, 7, 10, 15, 25, 
50, and 100 µM, in triplicate, were used for each assay. Buffer, enzyme, and inhibitor 
were combined. Cathepsin assays were activated by the injection of substrate. Calpain 
assays were activated by the injection of CaCl2 to a final concentration of 5 mM. All 
assays were done at a total well volume of 100 µL in 96-well plate, and each well 
contained a separate inhibitor concentration. Fluorescence was read in a Fluorescence 
readings were taken every 13 seconds for one hour by a Berthold Tri-Star plate reader.  
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Velocities were determined by taking only the linear portion of the curve into 
account (roughly 200-400 sec.). IC50 was determined by plotting the fractional activity 
vs. the log [I]. Fractional activity was calculated by dividing the velocity of the inhibited 
enzyme by the velocity of the uninhibited enzyme and multiplying by 100 to obtain a 
percentage. The initial rate was then plotted against the log of the inhibitor concentration, 
and IC50 was calculated by GraphPad Prism. Ki was calculated from the IC50 using the 
equation .142 Inhibitors were tested against purified enzyme. Bolded and 
underlined residues denote where the linker, α,α’-dibromo-m-xylene is attached. 
! 
K
i
=
IC
50
1+
[S]
K
m
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Cathepsin L Inhibitor Assays 
  
Figure S4.3: IC50 curve for SEEFRQVMNGF, 7a. 
 
Figure S4.4: IC50 curve for SECFRQCMNGF, 7b. 
   
  
Figure S4.5: IC50 curve for SCEFRCVMNGF, 7c. 
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Figure S4.6: IC50 curves for SCEnRCVMNGF, 7d. 
  
  
Figure S4.7: IC50 curves for SCEbRCVMNGF, 7e. 
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Figure S4.8: IC50 curves for SCEFRCVMNGn, 7f. 
  
  
Figure S4.9: IC50 curves for SCEbRCVMNGn, 7g. 
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Cathepsin S Inhibitor Assays 
   
Figure S4.10: IC50 curve for TSEEVMSLMSS, 8a. 
 
Figure S4.11: IC50 curve for TCEEVCSLMSS, 8b. 
  
  
Figure S4.12: IC50 curve for TSEEVCSLMCS, 2c. 
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Figure S4.13: IC50 curves for WSEEVCSLMCS, 8d. 
  
  
Figure S4.14: IC50 curves for TWEEVCSLMCS, 8e.  
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Figure S4.15: IC50 curves for TSEWVCSLMCS, 8f. 
  
  
Figure S4.16: IC50 curves for TSEEWCSLMCS, 8g. 
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Figure S4.17: IC50 curves for TWEWVCSLMCS, 8h. 
  
Figure S4.18: IC50 curves for TnEnVCSLMCS, 8i. 
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Figure S4.19: IC50 curves for WWEWVCSLMCS, 8j. 
  
   
Figure S4.20: IC50 curves for WWEWWCSLMCS, 8k.  
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Figure S4.21: IC50 curves for FFEFFCSLMCS, 8l. 
 
Figure S4.22: IC50 curves for WWEWbCSLMCS, 8m. 
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Cathepsin K Inhibitor Assays 
 
Figure S4.23: IC50 curve for SEEVVQKMTGL, 9a. 
  
  
Figure S4.24: IC50 curves for SCEVVCKMTGL, 9b. 
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Figure S4.25: IC50 curves for SCESVCKMTGL, 9c. 
 
Figure S4.26: IC50 curves for SCEHVCKMTGL, 9d. 
 
Figure S4.27: IC50 curves for SCENVCKMTGL, 9e. 
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Figure S4.28: IC50 curves for SCELVCKMTGL, 9f. 
  
  
Figure S4.29: IC50 curves for SCEVVCKPTGL, 9g. 
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Figure S4.30: IC50 curves for SCEVVCKMWGL, 9h. 
 
Figure S4.31: IC50 curves for SCEVVCKMFGL, 9i. 
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Figure S4.32: IC50 curves for SCEVVCKMTGP, 9j. 
 
Figure S4.33: IC50 curves for SCESVCKMTGP, 9k. 
 
Figure S4.34: IC50 curves for SCEVVCKPTGP, 9l. 
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Figure S4.35: IC50 curves for SCESVCKPWGP, 9m. 
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Michaelis-Menten Kinetics  
To identify inhibition type we used standard Michaelis-Menten treatment. Initial 
velocities were calculated from the linear segment of the progress curves then plotted 
against their substrate concentration (~200-400 s).142 Units were initially measured in 
RFU/sec then converted to µM/sec using the conversion factor 17567.8 RFU/µM for Z-
FR-Amc and 5999.04 RFU/µM for Z-VVR-Amc. The conversion factor was obtained by 
the total hydrolysis of the substrate in a known concentration by papain.  We then plotted 
velocity vs. substrate concentration and used GraphPadPrism program Michaelis-Menten 
(under kinetics) to determine the Kmapp and Vmaxapp. 
 
[7g] (µM) Vmaxapp (µM/sec) Kmapp 
0 0.002034 ± 0.0001 1.605 
0.025 0.002058 ± 0.0001 2.022 
0.05 0.002128 ± 0.0001 2.375 
Table S4.2: Cathepsin L inhibitor 7g Michaelis-Menten results. 
[8k] (µM)	   Vmaxapp (µM/sec)	   Kmapp	  
0	   0.06344 ± 0.0106	   29.96	  
0.5	   0.07103 ± 0.0348	   46.05	  
1	   0.07114 ± 0.0137	   50.16	  
Table S4.3: Cathepsin S inhibitor 8k Michaelis-Menten results. 
[9g] (µM)	   Vmaxapp (µM/sec)	   Kmapp	  
0	   0.006156 ± 0.0015	   50.21	  
0.5	   0.006261 ± 0.0012	   53.65	  
1	   0.006800± 0.0021	   65.30	  
Table S4.4: Cathepsin K inhibitor 9g Michaelis-Menten results. 
Vmaxapp is the same at all inhibitor concentrations while Kmapp increases with 
increasing inhibitor concentration. These results are indicative of competitive inhibition. 
To avoid weighting errors we used the values of Kmapp and Vmaxapp determined directly 
	  
	   148	  
from the non-linear least-squares best fits of the untransformed data and put these values 
into the reciprocal equation:  
  142 
We then plotted the resulting reciprocal velocities against the respective 
reciprocal substrate concentrations creating a Lineweaver-Burk plot to further identify 
mode of inhibition. All lines intersected at the x-axis indicating competitive kinetics. 
 
Lineweaver-Burk Plots 
 
Figure S4.36: Lineweaver-Burke plots demonstrating that the α-helical inhibitors are all competitive 
inhibitors suggesting that it is likely they are binding at the active site.  
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α-Helical Inhibitors Modeled in Enzyme Active Sites 
Using the zymogen crystal structures, the mutated, stabilized, α-helical inhibitors 
were modeled into the enzyme active site using Pymol as a visualization of their mode of 
inhibition.31 
 
Figure S4.37: Models of a stabilized, α-helical inhibitor in the active site of its respective enzyme. (A) 
Cathepsin L, 7g, (B) Cathepsin S, 8k, (C) Cathepsin K, 9g.31  
A B C
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